{"protocolSection":{"identificationModule":{"nctId":"NCT02367794","orgStudyIdInfo":{"id":"GO29437"},"secondaryIdInfos":[{"id":"2014-003208-59","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]","officialTitle":"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-06-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-10-03","type":"ACTUAL"},"completionDateStruct":{"date":"2021-02-17","type":"ACTUAL"},"studyFirstSubmitDate":"2015-02-13","studyFirstSubmitQcDate":"2015-02-13","studyFirstPostDateStruct":{"date":"2015-02-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-09-25","resultsFirstSubmitQcDate":"2019-10-21","resultsFirstPostDateStruct":{"date":"2019-11-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-17","lastUpdatePostDateStruct":{"date":"2022-03-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC."},"conditionsModule":{"conditions":["Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1021,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL","description":"The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody","Drug: Carboplatin","Drug: Paclitaxel"]},{"label":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","type":"EXPERIMENTAL","description":"The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody","Drug: Carboplatin","Drug: Nab-Paclitaxel"]},{"label":"Arm C: Nab-Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR","description":"The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.","interventionNames":["Drug: Carboplatin","Drug: Nab-Paclitaxel"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody","description":"Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.","armGroupLabels":["Arm A: Atezolizumab + Paclitaxel + Carboplatin","Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin"],"otherNames":["Tecentriq"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.","armGroupLabels":["Arm A: Atezolizumab + Paclitaxel + Carboplatin","Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","Arm C: Nab-Paclitaxel + Carboplatin"]},{"type":"DRUG","name":"Nab-Paclitaxel","description":"Nab-paclitaxel 100 milligrams per meter squared (mg/m\\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.","armGroupLabels":["Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","Arm C: Nab-Paclitaxel + Carboplatin"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel 200 mg/m\\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\\^2 IV.","armGroupLabels":["Arm A: Atezolizumab + Paclitaxel + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"Overall Survival (OS) in the ITT Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.","timeFrame":"Up to approximately 39 months after first participant enrolled"}],"secondaryOutcomes":[{"measure":"OS in the in the Teff Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.","timeFrame":"Up to approximately 39 months after first participant enrolled"},{"measure":"PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"OS in the TC2/3 or IC2/3 Population","description":"OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.","timeFrame":"Up to approximately 39 months after first participant enrolled"},{"measure":"OS in the TC1/2/3 or IC1/2/3 Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.","timeFrame":"Up to approximately 39 months after first participant enrolled"},{"measure":"Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population","description":"Proportion of participants with an objective response (CR or PR) in the ITT population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population","description":"Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"Event Free Rate at 1 and 2 Years in the ITT Population","description":"Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.","timeFrame":"1 and 2 years"},{"measure":"Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population","description":"TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population","description":"TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a \\>= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a \\>= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial\\>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A \\>= 10-point change in the EORTC scale score is perceived by patients as clinically significant.","timeFrame":"Up to approximately 30 months after the first participant enrolled"},{"measure":"Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population","description":"Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \\& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \\& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \\& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \\& 2, 'Cough' score is mean of question 3 \\& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \\& cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)","timeFrame":"Baseline up to approximately 30 months after first participant enrolled"},{"measure":"PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"OS in the ITT Population (Arm A and Arm B)","description":"OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.","timeFrame":"Up to approximately 39 months after first participant enrolled"},{"measure":"Percentage of Participants With Adverse Events","description":"Percentage of participants with at least one adverse event.","timeFrame":"Up to approximately 68 months after first participant enrolled"},{"measure":"Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab","description":"Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.","timeFrame":"Up to approximately 30 months after first participant enrolled"},{"measure":"Maximum Observed Serum Atezolizumab Concentration (Cmax)","description":"Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.","timeFrame":"Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)"},{"measure":"Minimum Observed Serum Atezolizumab Concentration (Cmin)","description":"Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.","timeFrame":"Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)"},{"measure":"Plasma Concentrations for Paclitaxel","description":"Plasma concentrations for paclitaxel.","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)"},{"measure":"Plasma Concentrations for Nab-Paclitaxel","description":"Plasma concentrations for nab-paclitaxel.","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)"},{"measure":"Plasma Concentrations for Carboplatin","description":"Plasma concentrations for carboplatin.","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC\n* Previously obtained archival tumor tissue or tissue obtained from biopsy at screening\n* Measurable disease as defined by RECIST v1.1\n* Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n* Active or untreated central nervous system (CNS) metastasis\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* Pregnant or lactating women\n* History of autoimmune disease\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Positive test for Human Immunodeficiency Virus (HIV)\n* Active hepatitis B or hepatitis C\n* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody\n* Severe infection within 4 weeks prior to randomization\n* Significant history of cardiovascular disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ironwood Cancer & Research Centers","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Highlands Oncology Group","city":"Springdale","state":"Arkansas","zip":"72762","country":"United States","geoPoint":{"lat":36.18674,"lon":-94.12881}},{"facility":"Southern CA Permanente Med Grp","city":"Bellflower","state":"California","country":"United States","geoPoint":{"lat":33.88168,"lon":-118.11701}},{"facility":"Kaiser Permanente Oakland Medical Center","city":"Oakland","state":"California","zip":"94611","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"Kaiser Permanente - Sacramento Medical Center and Medical Offices","city":"Sacramento","state":"California","zip":"95825","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Kaiser Permanente - San Leandro Medical Center","city":"San Leandro","state":"California","zip":"94577","country":"United States","geoPoint":{"lat":37.72493,"lon":-122.15608}},{"facility":"Kaiser Permanente - Santa Clara","city":"Santa Clara","state":"California","zip":"95051","country":"United States","geoPoint":{"lat":37.35411,"lon":-121.95524}},{"facility":"Kaiser Permanente; Oncology Clinical Trials","city":"Vallejo","state":"California","zip":"94589","country":"United States","geoPoint":{"lat":38.10409,"lon":-122.25664}},{"facility":"Kaiser Permanente - Walnut Creek","city":"Walnut Creek","state":"California","zip":"94596","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Rocky Mountain Cancer Center","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Danbury Hospital","city":"Danbury","state":"Connecticut","zip":"06810","country":"United States","geoPoint":{"lat":41.39482,"lon":-73.45401}},{"facility":"Holy Cross Hospital Inc","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"SCRI Florida Cancer Specialists South","city":"Fort Myers","state":"Florida","zip":"33916","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Florida Cancer Specialists","city":"Palm Beach Gardens","state":"Florida","zip":"33410","country":"United States","geoPoint":{"lat":26.82339,"lon":-80.13865}},{"facility":"Hematology Oncology Associates of the Treasure Coast","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"University Cancer & Blood Center, LLC; Research","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital","city":"Carrollton","state":"Georgia","zip":"30117","country":"United States","geoPoint":{"lat":33.58011,"lon":-85.07661}},{"facility":"Central Georgia Cancer Care PC","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"Southeastern Regional Medical Center, Inc.","city":"Newnan","state":"Georgia","zip":"30265","country":"United States","geoPoint":{"lat":33.38067,"lon":-84.79966}},{"facility":"University of Chicago","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Joliet Oncology-Hematology; Associates, Ltd.","city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"Quincy Medical Group","city":"Quincy","state":"Illinois","zip":"62301","country":"United States","geoPoint":{"lat":39.9356,"lon":-91.40987}},{"facility":"Fort Wayne Med Oncology & Hematology Inc","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Hematology-Oncology; Associates of the Quad Cities","city":"Bettendorf","state":"Iowa","zip":"52722","country":"United States","geoPoint":{"lat":41.52448,"lon":-90.51569}},{"facility":"Siouxland Hematology/Oncology","city":"Sioux City","state":"Iowa","zip":"51101","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"Lahey Clinic Med Ctr","city":"Lexington","state":"Kentucky","zip":"02421","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Norton Cancer Institute","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Ochsner Clinic Foundation","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"New England Cancer Specialists","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"Southcoast Health System; Southcoast Centers For Cancer Care","city":"Fairhaven","state":"Massachusetts","zip":"02719","country":"United States","geoPoint":{"lat":41.6376,"lon":-70.90365}},{"facility":"St. Joseph Mercy Health System","city":"Ann Arbor","state":"Michigan","zip":"48106","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"St. Luke's Regional Cancer Center","city":"Duluth","state":"Minnesota","zip":"55805","country":"United States","geoPoint":{"lat":46.78327,"lon":-92.10658}},{"facility":"Hematology and Oncology Associates at Bridgepoint","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"Billings Clinic","city":"Billings","state":"Montana","zip":"59102","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Valley Hospital; Oncology Research","city":"Paramus","state":"New Jersey","zip":"07652","country":"United States","geoPoint":{"lat":40.94454,"lon":-74.07542}},{"facility":"Regional Cancer Care Associates LLC","city":"Sewell","state":"New Jersey","zip":"08080","country":"United States","geoPoint":{"lat":39.7665,"lon":-75.14434}},{"facility":"Clinical Research Alliance","city":"Westbury","state":"New York","zip":"11590","country":"United States","geoPoint":{"lat":40.75566,"lon":-73.58763}},{"facility":"W.G. Bill Hefner VA Medical Center","city":"Salisbury","state":"North Carolina","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"University of Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45203-0542","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Mark H. Zangmeister Center","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Oncology Hematology Care, Inc.","city":"Hamilton","state":"Ohio","zip":"45103","country":"United States","geoPoint":{"lat":39.3995,"lon":-84.56134}},{"facility":"Oregon Health & Science Uni","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"St. Luke's Cancer Care Associates","city":"Bethlehem","state":"Pennsylvania","zip":"18015","country":"United States","geoPoint":{"lat":40.62593,"lon":-75.37046}},{"facility":"Maryland Oncology Hematology (Lanham) - USOR","city":"Gettysburg","state":"Pennsylvania","zip":"17325","country":"United States","geoPoint":{"lat":39.83093,"lon":-77.2311}},{"facility":"Allegheny Cancer Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Univ of Pittsburgh Medical Ctr","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"SCRI Tennessee Oncology Chattanooga","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Tennessee Cancer Specialists","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"SCRI The Center For Cancer and Blood Disorders","city":"Denton","state":"Texas","zip":"76210","country":"United States","geoPoint":{"lat":33.21484,"lon":-97.13307}},{"facility":"Longview Cancer Center","city":"Longview","state":"Texas","zip":"75601","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Virginia Oncology Associates","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Blue Ridge Cancer Care","city":"Roanoke","state":"Virginia","zip":"24014","country":"United States","geoPoint":{"lat":37.27097,"lon":-79.94143}},{"facility":"Providence Regional Cancer Partnership","city":"Everett","state":"Washington","zip":"98201","country":"United States","geoPoint":{"lat":47.97898,"lon":-122.20208}},{"facility":"Medical Oncology Associates","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Fundación CENIT para la Investigación en Neurociencias","city":"Buenos Aires","zip":"C1125ABD","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Sanatorio Allende","city":"Córdoba","zip":"X5000JHQ","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Centro Oncologico Riojano Integral (CORI)","city":"La Rioja","zip":"F5300COE","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Clínica Pergamino","city":"Pergamino","zip":"B2700CPM","country":"Argentina","geoPoint":{"lat":-33.89101,"lon":-60.57462}},{"facility":"Fundacion Koriza","city":"Santa Rosa","zip":"L6304BOC","country":"Argentina","geoPoint":{"lat":-36.61617,"lon":-64.28991}},{"facility":"Centro de Investigacion; Clinica - Clinica Viedma S.A.","city":"Viedma","zip":"R8500ACE","country":"Argentina","geoPoint":{"lat":-40.81519,"lon":-63.0004}},{"facility":"Chris O'Brien Lifehouse","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Calvary Mater Newcastle; Medical Oncology","city":"Waratah","state":"New South Wales","zip":"2298","country":"Australia","geoPoint":{"lat":-32.90667,"lon":151.72647}},{"facility":"Prince Charles Hospital","city":"Chermside","state":"Queensland","zip":"4032","country":"Australia","geoPoint":{"lat":-27.38472,"lon":153.03062}},{"facility":"Townsville Hospital","city":"Townsville","state":"Queensland","zip":"4810","country":"Australia","geoPoint":{"lat":-19.26639,"lon":146.80569}},{"facility":"Princess Alexandra Hospital","city":"Woolloongabba","state":"Queensland","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Royal Adelaide Hospital","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Austin Health","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Cabrini Hospital Malvern","city":"Malvern","state":"Victoria","zip":"3144","country":"Australia","geoPoint":{"lat":-37.86259,"lon":145.02811}},{"facility":"Sunshine Hospital","city":"St Albans","state":"Victoria","zip":"3021","country":"Australia","geoPoint":{"lat":-37.74496,"lon":144.80049}},{"facility":"Sir Charles Gairdner Hospital","city":"Nedlands","state":"Western Australia","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Paracelsus Medizinische Privatuniversität","city":"Salzburg","zip":"5020","country":"Austria","geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"Cliniques Universitaires St-Luc","city":"Brussels","zip":"1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"CHU Sart-Tilman","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Clinique Ste-Elisabeth","city":"Namur","zip":"5000","country":"Belgium","geoPoint":{"lat":50.4669,"lon":4.86746}},{"facility":"Werken Glorieux VZW","city":"Ronse","zip":"9600","country":"Belgium","geoPoint":{"lat":50.74574,"lon":3.6005}},{"facility":"GasthuisZusters Antwerpen","city":"Wilrijk","zip":"2610","country":"Belgium","geoPoint":{"lat":51.16734,"lon":4.39513}},{"facility":"Cenantron - Centro Avancado de Tratamento Oncologico","city":"Belo Horizonte","state":"Minas Gerais","zip":"30130-090","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica","city":"Londrina","state":"Paraná","zip":"86 015 520","country":"Brazil","geoPoint":{"lat":-23.31028,"lon":-51.16278}},{"facility":"Liga Norte Riograndense Contra O Câncer","city":"Natal","state":"Rio Grande do Norte","zip":"59040150","country":"Brazil","geoPoint":{"lat":-5.795,"lon":-35.20944}},{"facility":"IPCEM; Instituto de Pesquisa de Estudos Multicêntricos","city":"Caxias do Sul","state":"Rio Grande do Sul","zip":"95070-560","country":"Brazil","geoPoint":{"lat":-29.16806,"lon":-51.17944}},{"facility":"Hospital Bruno Born","city":"Lajeado","state":"Rio Grande do Sul","zip":"95900-000","country":"Brazil","geoPoint":{"lat":-29.46694,"lon":-51.96139}},{"facility":"Hospital das Clinicas - UFRGS","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90035-903","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Mae de Deus","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90470-340","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"*X*Fundação Pio XII Hospital de Câncer de Barretos","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Hospital de Base de Sao Jose do Rio Preto","city":"São José do Rio Preto","state":"São Paulo","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Hospital Do Cancer A C Camargo","city":"São Paulo","state":"São Paulo","zip":"01525-001","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Multiprofile Hospital for Active Treatment Central Onco Hospital OOD","city":"Plovdiv","zip":"4000","country":"Bulgaria","geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Multiprofile Hospital for Active Treatment Serdika EOOD","city":"Sofia","zip":"1303","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Royal Victoria Regional Health Centre","city":"Barrie","state":"Ontario","zip":"L4M 6M2","country":"Canada","geoPoint":{"lat":44.40011,"lon":-79.66634}},{"facility":"William Osler Health Centre","city":"Etobicoke","state":"Ontario","zip":"M9V 1R8","country":"Canada","geoPoint":{"lat":43.64415,"lon":-79.56985}},{"facility":"Lakeridge Health Center","city":"Oshawa","state":"Ontario","zip":"L1J 2J2","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"facility":"Cite de La Sante de Laval; Hemato-Oncologie","city":"Laval","state":"Quebec","zip":"H7M 3L9","country":"Canada","geoPoint":{"lat":45.56995,"lon":-73.692}},{"facility":"Hôpital du Sacré-Coeur de Montreal","city":"Montreal","state":"Quebec","zip":"H4J 1C5","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"St. Jerome Medical Research","city":"Saint-Jérôme","state":"Quebec","zip":"J7Z 5T3","country":"Canada","geoPoint":{"lat":45.78036,"lon":-74.00365}},{"facility":"Health & Care SPA","city":"Santiago","zip":"7500006","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Sociedad de Investigaciones Medicas Ltda (SIM)","city":"Temuco","zip":"4810469","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"CHU de Grenoble","city":"Grenoble","zip":"38043","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd","city":"Le Mans","zip":"72000","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes","city":"Lyon","zip":"69008","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Clinique Clémentville","city":"Montpellier","zip":"34070","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Hopital de La Source","city":"Orléans","zip":"45067","country":"France","geoPoint":{"lat":47.90248,"lon":1.90407}},{"facility":"Centre Hospitalier Lyon Sud","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Hopital de Pontchaillou; Service de Pneumologie","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Centre Hospitalier Regional Sud Reunion; Service de Pneumologie","city":"Saint-Pierre","zip":"97448","country":"France","geoPoint":{"lat":43.29282,"lon":5.40682}},{"facility":"CH de Saint Quentin","city":"Saint-Quentin","zip":"2100","country":"France","geoPoint":{"lat":49.84889,"lon":3.28757}},{"facility":"Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques","city":"Toulon","zip":"83800","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Charite - Universitätsmedizin Berlin","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie","city":"Bielefeld","zip":"33611","country":"Germany","geoPoint":{"lat":52.03333,"lon":8.53333}},{"facility":"Augusta Kranken-Anstalt gGmbH","city":"Bochum","zip":"44791","country":"Germany","geoPoint":{"lat":51.48165,"lon":7.21648}},{"facility":"Kliniken der Stadt Koln gGmbH","city":"Cologne","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Universitätsklinikum \"Carl Gustav Carus\" der Technischen Universität Dresden","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"St. Elisabethen Krankenhaus","city":"Frankfurt am Main","zip":"60487","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie","city":"Gerlingen","zip":"70839","country":"Germany","geoPoint":{"lat":48.79954,"lon":9.06316}},{"facility":"LungenClinic Großhansdorf GmbH","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Krankenhaus Martha-Maria; Halle-Dolau gGmbH","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Universitätsklinikum Hamburg-Eppendorf","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Asklepios Klinik Harburg","city":"Hamburg","zip":"21075","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Lungenklinik Hemer","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Universität Des Saarlandes; Klinik für Innere Medizin V","city":"Homburg","zip":"66421","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Fachklinik für Lungenerkrankungen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin","city":"Minden","zip":"32429","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"facility":"Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie","city":"München","zip":"81925","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Krankenhaus Barmherzige Bruder Regensburg","city":"Regensburg","zip":"93049","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Klinikum der Universität Regensburg","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Stiftung Mathias-Spital Rheine","city":"Rheine","zip":"48431","country":"Germany","geoPoint":{"lat":52.28509,"lon":7.44055}},{"facility":"Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie","city":"Villingen-Schwenningen","zip":"78052","country":"Germany","geoPoint":{"lat":48.06226,"lon":8.49358}},{"facility":"Soroka Medical Center","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Hadassah University Hospital - Ein Kerem","city":"Jerusalem","zip":"9112001","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Meir Medical Center; Oncology","city":"Kfar Saba","zip":"4428164","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Rabin Medical Center","city":"Petach Tiqwa","zip":"4941492","country":"Israel"},{"facility":"Chaim Sheba Medical Center; Oncology Dept","city":"Ramat Gan","zip":"5262100","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Rambam Health Corporation; Oncology Institute","city":"Rambam","zip":"3525408","country":"Israel"},{"facility":"Tel Aviv Sourasky Medical Ctr; Oncology","city":"Tel Aviv","zip":"6423906","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"IRCCS Giovanni Paolo II Istituto Oncologico","city":"Bari","state":"Apulia","zip":"70124","country":"Italy","geoPoint":{"lat":41.12066,"lon":16.86982}},{"facility":"Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati","city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"AORN A Cardarelli","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Azienda Ospedaliera San Camillo Forlanini","city":"Rome","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"ASL 3 Genovese; DSM","city":"Genoa","state":"Liguria","zip":"16147","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94439}},{"facility":"Fondazione IRCCS Policlinico San Matteo","city":"Pavia","state":"Lombardy","zip":"27100","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"facility":"Policlinico Vittorio Emanuele","city":"Catania","state":"Sicily","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Ospedale Civile - Livorno","city":"Livorno","state":"Tuscany","zip":"57124","country":"Italy","geoPoint":{"lat":43.54427,"lon":10.32615}},{"facility":"Azienda Ospedaliero Universitaria Pisana","city":"Pisa","state":"Tuscany","zip":"56100","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Ospedale Silvestrini","city":"Perugia","state":"Umbria","zip":"06122","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Aichi Cancer Center Hospital; Respiratory Medicine","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"Nagoya University Hospital; Respiratory Medicine","city":"Aichi","zip":"466-8560","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"National Cancer Center Hospital East; Thoracic Oncology","city":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"National Hospital Organization Shikoku Cancer Center; Internal Medicine","city":"Ehime","zip":"791-0280","country":"Japan"},{"facility":"National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kyushu University Hospital; Respiratory","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kobe City Medical Center General Hospital; Respiratory Medicine","city":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"National Hospital Organization Himeji Medical Center","city":"Hyōgo","zip":"670-8520","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"Hyogo Cancer Center; Thoracic Oncology","city":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"Ibaraki Prefectural Central Hospital; Division of respiratory","city":"Ibaraki","zip":"309-1793","country":"Japan","geoPoint":{"lat":34.81641,"lon":135.56828}},{"facility":"Kanagawa Cancer Center;Thoracic Oncology","city":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Kyoto University Hospital, Respiratory Medicine","city":"Kyoto","zip":"606-8507","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Sendai Kousei Hospital; Pulmonary Medicine","city":"Miyagi","zip":"980-0873","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease","city":"Niigata","zip":"951-8520","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Okayama University Hospital; Respiratory and Allergy Medicine","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka International Cancer Institute; Thoracic Oncology","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka City Uni Hospital; Respiratory Medicine","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kansai Medical university Hospital; Thoracic Oncology","city":"Osaka","zip":"573-1191","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka Habikino Medical Center","city":"Osaka","zip":"583-8588","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"National Hospital Organization Kinki-Chuo Chest Medical Center","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Saitama Cancer Center; Thoracic Oncology","city":"Satima","zip":"362-0806","country":"Japan"},{"facility":"Shizuoka Cancer Center; Thoracic Oncology","city":"Shizuoka","zip":"411-8777","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"National Cancer Center Hospital; Thoracic Medical Oncology","city":"Tokyo","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Tokyo Medical University Hospital; Dept of Surgery","city":"Tokyo","zip":"160-0023","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Pauls Stradins Clinical University Hospital","city":"Riga","zip":"LV-1002","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"Riga East Clinical University Hospital Latvian Oncology Centre","city":"Riga","zip":"LV-1079","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"National Cancer Institute","city":"Vilnius","zip":"08660","country":"Lithuania","geoPoint":{"lat":54.68916,"lon":25.2798}},{"facility":"Centro Universitario Contra El Cancer","city":"Monterrey","zip":"64020","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Cancerología","city":"Querétaro","zip":"76090","country":"Mexico","geoPoint":{"lat":15.83752,"lon":-92.75774}},{"facility":"VU Medisch Centrum; VU University Medical Center","city":"Amsterdam","zip":"1007 MB","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis","city":"Amsterdam","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Ziekenhuis Gelderse Vallei","city":"Ede","zip":"6716 RP","country":"Netherlands","geoPoint":{"lat":52.03333,"lon":5.65833}},{"facility":"Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose","city":"Eindhoven","zip":"5623 EJ","country":"Netherlands","geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"St. Antonius Ziekenhuis; R&D Long","city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Centro Medico Monte Carmelo","city":"Arequipa","zip":"04001","country":"Peru","geoPoint":{"lat":-16.39899,"lon":-71.53747}},{"facility":"Hospital Nacional Guillermo Almenara Irigoyen ESSALUD","city":"Lima","zip":"Lima 13","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Instituto Regional de Enfermedades Neoplásicas Del Norte","city":"Trujillo","zip":"12345","country":"Peru","geoPoint":{"lat":-8.11599,"lon":-79.02998}},{"facility":"IPO de Lisboa; Servico de Pneumologia","city":"Lisbon","zip":"1099-023","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Hospital Pulido Valente; Servico de Pneumologia","city":"Lisbon","zip":"1796-001","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Centro Hospitalar do Porto - Hospital de Santo António","city":"Porto","zip":"4099-001","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Hospital de Sao Joao; Servico de Pneumologia","city":"Porto","zip":"4200","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Moscow City Oncology Hospital #62","city":"Moscovskaya Oblast","state":"Moscow Oblast","zip":"143423","country":"Russia"},{"facility":"Russian Oncology Research Center n.a. N.N. Blokhin","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Clinical Oncology Dispensary","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"City Clinical Oncology Dispensary","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Volgograd Regional Clinical Oncology Dispensary","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"National University Hospital","city":"Singapore","zip":"119074","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Centre","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Univerzitna nemocnica Bratislava","city":"Bratislava","zip":"813 69","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Narodny onkologicky ustav","city":"Bratislava","zip":"833 10","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"POKO Poprad s.r.o.","city":"Poprad","zip":"058 01","country":"Slovakia","geoPoint":{"lat":49.06144,"lon":20.29798}},{"facility":"Hospital Universitario Son Espases","city":"Palma de Mallorca","state":"Balearic Islands","zip":"07014","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Corporacio Sanitaria Parc Tauli; Servicio de Oncologia","city":"Sabadell","state":"Barcelona","zip":"8208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Hospital Universitario Marques de Valdecilla; Servicio de Oncologia","city":"Santander","state":"Cantabria","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Complejo Hospitalario Universitario A Coruña","city":"A Coruña","state":"LA Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Complejo Hospitalario Universitario Insular-Materno Infantil","city":"Las Palmas de Gran Canaria","state":"LAS Palmas","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Hospital Nuestra Senora de Valme","city":"Seville","state":"Sevilla","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario de Canarias","city":"S. Cristobal de La Laguna","state":"Tenerife","zip":"38320","country":"Spain"},{"facility":"Hospital del Mar","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Univ Vall d'Hebron; Servicio de Oncologia","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clinic de Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Reina Sofia","city":"Córdoba","zip":"14008","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hospital Lucus Augusti; Servicio de Oncologia","city":"Lugo","zip":"27003","country":"Spain","geoPoint":{"lat":43.00992,"lon":-7.55602}},{"facility":"Hospital General Universitario Gregorio Marañon; Servicio de Oncologia","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz","city":"Madrid","zip":"280146","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Ramon y Cajal; Servicio de Oncologia","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Fundación Jimenez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico San Carlos; Servicio de Oncologia","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico Universitario de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital General Universitario de Valencia","city":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitario Miguel Servet","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Changhua Christian Hospital; Hematology-Oncology","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Kaohsiung Medical University Hospital; Department of Urology","city":"Kaohsiung City","zip":"807","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Chi Mei Medical Center Liou Ying Campus","city":"Liuying Township","zip":"736","country":"Taiwan"},{"facility":"Chang Gung Memorial Hospital Chiayi","city":"Putzu","zip":"613","country":"Taiwan"},{"facility":"China Medical University Hospital","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Taiwan Uni Hospital","city":"Taipei","zip":"10041","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Mackay Memorial Hospital","city":"Taipei","zip":"104","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy","city":"Dnipropetrovsk","state":"Katerynoslav Governorate","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Uzhgorod Central City Clinical Hospital","city":"Uzhhorod","state":"Katerynoslav Governorate","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"MNPE Zaporizhzhia Regional Antitumor Center ZRC","city":"Zaporizhzhia","state":"Katerynoslav Governorate","zip":"69040","country":"Ukraine","geoPoint":{"lat":47.15214,"lon":35.74246}},{"facility":"Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs","city":"Kharkiv","state":"Kharkiv Governorate","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council","city":"Vinnytsia","state":"KIEV Governorate","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy","city":"Lviv","state":"Volhynian Governorate","zip":"79031","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1","city":"Chernivtsi","zip":"58013","country":"Ukraine","geoPoint":{"lat":48.29045,"lon":25.93241}},{"facility":"SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine","city":"Kharkiv","zip":"61024","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department","city":"Kryvyi Rih","zip":"50048","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department","city":"Poltava","zip":"36011","country":"Ukraine","geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary","city":"Sumy","zip":"40005","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}}]},"referencesModule":{"references":[{"pmid":"35511917","type":"DERIVED","citation":"Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"'Study Terminated By Sponsor' Reason for Not Completed is a data entry error; reason for not completed is unknown. The study was Completed and not Terminated.","groups":[{"id":"FG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"FG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"FG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"340"},{"groupId":"FG001","numSubjects":"343"},{"groupId":"FG002","numSubjects":"338"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"340"},{"groupId":"FG001","numSubjects":"343"},{"groupId":"FG002","numSubjects":"338"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"252"},{"groupId":"FG001","numSubjects":"245"},{"groupId":"FG002","numSubjects":"243"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"20"}]},{"type":"Brain metastasis","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Randomized in error","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Patient unable to receive carboplatin","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Hypercalcemia prior to C1D1","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Study Terminated By Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Moved to Roll-Over Study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"13"}]},{"type":"Sponsor Request","reasons":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"57"},{"groupId":"FG002","numSubjects":"45"}]},{"type":"Moved into PTAP Study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Moved to Commercial Atezolizumab Use","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Investigational Product Availability in Commercial Stock","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Participant Enrolled in Extended Protocol","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Discontinuation Matched Treatment Discontinuation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"BG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"BG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"340"},{"groupId":"BG001","value":"343"},{"groupId":"BG002","value":"338"},{"groupId":"BG003","value":"1021"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.9","spread":"8.1"},{"groupId":"BG001","value":"64.0","spread":"9.2"},{"groupId":"BG002","value":"65.0","spread":"8.3"},{"groupId":"BG003","value":"64.6","spread":"8.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"186"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"277"},{"groupId":"BG001","value":"280"},{"groupId":"BG002","value":"278"},{"groupId":"BG003","value":"835"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"79"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"297"},{"groupId":"BG003","value":"902"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"40"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"112"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"14"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"290"},{"groupId":"BG001","value":"289"},{"groupId":"BG002","value":"290"},{"groupId":"BG003","value":"869"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"8"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"343"},{"groupId":"OG002","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"5.5","upperLimit":"5.7"},{"groupId":"OG001","value":"6.5","lowerLimit":"5.7","upperLimit":"7.1"},{"groupId":"OG002","value":"5.6","lowerLimit":"5.5","upperLimit":"6.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0006","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"0.88"}]},{"type":"PRIMARY","title":"Overall Survival (OS) in the ITT Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 39 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"343"},{"groupId":"OG002","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"12.2","upperLimit":"15.1"},{"groupId":"OG001","value":"14.2","lowerLimit":"12.3","upperLimit":"16.8"},{"groupId":"OG002","value":"12.6","lowerLimit":"11.6","upperLimit":"14.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1581","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.05"}]},{"type":"SECONDARY","title":"OS in the in the Teff Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.","populationDescription":"The Teff (\\>=-1.91) population and the Teff (\\<-1.91) population, defined as patients in the ITT population with Teff signature expression \\>=-1.91 and \\<-1.91, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Month","timeFrame":"Up to approximately 39 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"313"},{"groupId":"OG002","value":"308"}]}],"classes":[{"title":"Teff >=-1.91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"12.2","upperLimit":"19.7"},{"groupId":"OG001","value":"17.4","lowerLimit":"12.3","upperLimit":"23.8"},{"groupId":"OG002","value":"15.2","lowerLimit":"13.4","upperLimit":"22.8"}]}]},{"title":"Teff<-1.91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"11.2","upperLimit":"14.3"},{"groupId":"OG001","value":"13.0","lowerLimit":"11.4","upperLimit":"14.8"},{"groupId":"OG002","value":"10.5","lowerLimit":"9.1","upperLimit":"12.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Teff \\>=-1.91 in ITT","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.4451","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.876","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.623","ciUpperLimit":"1.231"},{"groupIds":["OG000","OG002"],"groupDescription":"Teff \\>=-1.91 in ITT","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.7343","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.941","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.664","ciUpperLimit":"1.335"},{"groupIds":["OG000","OG001"],"groupDescription":"Teff \\<-1.91 Negative in ITT","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.6610","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.942","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.720","ciUpperLimit":"1.232"},{"groupIds":["OG000","OG002"],"groupDescription":"Teff \\<-1.91 Negative in ITT","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0893","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.253","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.965","ciUpperLimit":"1.627"}]},{"type":"SECONDARY","title":"PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.","populationDescription":"The Teff (\\>=-1.91) population and the Teff (\\<-1.91) population, defined as patients in the ITT population with Teff signature expression \\>=-1.91 and \\<-1.91, respectively.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"313"},{"groupId":"OG002","value":"308"}]}],"classes":[{"title":"Teff >=-1.91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"5.1","upperLimit":"5.7"},{"groupId":"OG001","value":"7.0","lowerLimit":"5.5","upperLimit":"8.5"},{"groupId":"OG002","value":"7.0","lowerLimit":"5.6","upperLimit":"9.7"}]}]},{"title":"Teff<-1.91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"5.5","upperLimit":"6.6"},{"groupId":"OG001","value":"6.2","lowerLimit":"5.6","upperLimit":"7.0"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.5","upperLimit":"5.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Teff\\>=-1.91","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0006","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"0.81"},{"groupIds":["OG000","OG002"],"groupDescription":"Teff\\>=-1.91","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.630","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.33"},{"groupIds":["OG000","OG001"],"groupDescription":"Teff\\<-1.91","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.258","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"1.10"},{"groupIds":["OG000","OG002"],"groupDescription":"Teff\\<-1.91","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.630","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.33"}]},{"type":"SECONDARY","title":"PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.","populationDescription":"The PD-L1 TC2/3 or IC2/3 population is defined as particpants in the ITT population with PD-L1 TC2/3 or IC2/3 expression in baseline tumor tissue.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"5.1","upperLimit":"5.7"},{"groupId":"OG001","value":"8.4","lowerLimit":"6.8","upperLimit":"10.4"},{"groupId":"OG002","value":"7.0","lowerLimit":"5.6","upperLimit":"8.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"<.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"0.72"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.0018","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.45","ciUpperLimit":"0.84"}]},{"type":"SECONDARY","title":"PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.","populationDescription":"The PD-L1 TC1/2/3 or IC1/2/3 population is defined as participants in the ITT population with PD-L1 TC1/2/3 or IC1/2/3 expression in baseline tumor tissue.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"167"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"5.3","upperLimit":"5.7"},{"groupId":"OG001","value":"7.1","lowerLimit":"5.8","upperLimit":"8.3"},{"groupId":"OG002","value":"7.0","lowerLimit":"5.6","upperLimit":"8.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"<.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"0.77"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"<.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"0.77"}]},{"type":"SECONDARY","title":"OS in the TC2/3 or IC2/3 Population","description":"OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.","populationDescription":"The PD-L1 TC2/3 or IC2/3 population is defined as particpants in the ITT population with PD-L1 TC2/3 or IC2/3 expression in baseline tumor tissue.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 39 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"12.1","upperLimit":"17.2"},{"groupId":"OG001","value":"20.4","lowerLimit":"13.8","upperLimit":"24.1"},{"groupId":"OG002","value":"14.8","lowerLimit":"11.1","upperLimit":"23.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.0518","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.725","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.524","ciUpperLimit":"1.004"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.2841","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.832","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.594","ciUpperLimit":"1.165"}]},{"type":"SECONDARY","title":"OS in the TC1/2/3 or IC1/2/3 Population","description":"OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.","populationDescription":"The PD-L1 TC1/2/3 or IC1/2/3 population is defined as participants in the ITT population with PD-L1 TC1/2/3 or IC1/2/3 expression in baseline tumor tissue.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 39 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"167"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"12.4","upperLimit":"17.2"},{"groupId":"OG001","value":"14.8","lowerLimit":"12.1","upperLimit":"19.6"},{"groupId":"OG002","value":"14.9","lowerLimit":"12.5","upperLimit":"18.2"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.2956","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.871","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.671","ciUpperLimit":"1.129"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.2473","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.861","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.668","ciUpperLimit":"1.109"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population","description":"Proportion of participants with an objective response (CR or PR) in the ITT population.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"342"},{"groupId":"OG002","value":"337"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0"},{"groupId":"OG001","value":"49.7"},{"groupId":"OG002","value":"49.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0248","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.04","ciUpperLimit":"1.91"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0308","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.03","ciUpperLimit":"1.90"}]},{"type":"SECONDARY","title":"Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population","description":"Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"4.4","upperLimit":"5.6"},{"groupId":"OG001","value":"7.2","lowerLimit":"6.8","upperLimit":"9.5"},{"groupId":"OG002","value":"7.0","lowerLimit":"5.7","upperLimit":"8.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"<.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.530","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.408","ciUpperLimit":"0.689"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified Analysis","pValue":"0.0007","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.640","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.493","ciUpperLimit":"0.831"}]},{"type":"SECONDARY","title":"Event Free Rate at 1 and 2 Years in the ITT Population","description":"Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.","populationDescription":"Participants still alive at 1 or 2 years after randomization from the ITT population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"1 and 2 years","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"170"}]}],"classes":[{"title":"1 Year","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"170"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.28"},{"groupId":"OG001","value":"56.34"},{"groupId":"OG002","value":"52.30"}]}]},{"title":"2 Year","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.58"},{"groupId":"OG001","value":"32.51"},{"groupId":"OG002","value":"27.79"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Event Free Rate (%) at Year 1","nonInferiorityType":"SUPERIORITY","pValue":"0.9871","statisticalMethod":"Z-test","paramType":"Difference in Event Free Rate","paramValue":"0.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.48","ciUpperLimit":"7.61"},{"groupIds":["OG000","OG001"],"groupDescription":"Event Free Rate (%) at Year 2","nonInferiorityType":"SUPERIORITY","pValue":"0.1133","statisticalMethod":"Z-test","paramType":"Difference in Event Free Rate","paramValue":"5.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.41","ciUpperLimit":"13.26"},{"groupIds":["OG000","OG002"],"groupDescription":"Event Free Rate (%) at Year 1","nonInferiorityType":"SUPERIORITY","pValue":"0.3072","statisticalMethod":"Z-test","paramType":"Difference in Event Free Rate","paramValue":"-3.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-11.60","ciUpperLimit":"3.65"},{"groupIds":["OG000","OG002"],"groupDescription":"Event Free Rate (%) at Year 2","nonInferiorityType":"SUPERIORITY","pValue":"0.7430","statisticalMethod":"Z-test","paramType":"Difference in Event Free Rate","paramValue":"1.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.01","ciUpperLimit":"8.42"}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population","description":"TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"343"},{"groupId":"OG002","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.6","upperLimit":"4.1"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.2","upperLimit":"5.6"},{"groupId":"OG002","value":"3.0","lowerLimit":"2.6","upperLimit":"3.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0461","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.797","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.638","ciUpperLimit":"0.996"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.7295","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.040","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.834","ciUpperLimit":"1.296"}]},{"type":"SECONDARY","title":"TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population","description":"TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a \\>= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a \\>= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial\\>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A \\>= 10-point change in the EORTC scale score is perceived by patients as clinically significant.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after the first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"343"},{"groupId":"OG002","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"2.2","upperLimit":"3.0"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.7","upperLimit":"5.1"},{"groupId":"OG002","value":"2.8","lowerLimit":"2.1","upperLimit":"3.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0942","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.828","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.663","ciUpperLimit":"1.033"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.7709","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.968","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.776","ciUpperLimit":"1.207"}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population","description":"Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \\& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \\& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \\& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \\& 2, 'Cough' score is mean of question 3 \\& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \\& cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"215"},{"groupId":"OG002","value":"195"}]}],"classes":[{"title":"Chest Pain, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.93"},{"groupId":"OG001","value":"0.14","spread":"0.87"},{"groupId":"OG002","value":"0.44","spread":"1.03"}]}]},{"title":"Chest Pain, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.89"},{"groupId":"OG001","value":"0.09","spread":"0.98"},{"groupId":"OG002","value":"0.28","spread":"1.00"}]}]},{"title":"Chest Pain, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.95"},{"groupId":"OG001","value":"-0.03","spread":"0.78"},{"groupId":"OG002","value":"-0.05","spread":"1.00"}]}]},{"title":"Chest Pain, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.98"},{"groupId":"OG001","value":"-0.05","spread":"0.98"},{"groupId":"OG002","value":"0.09","spread":"1.12"}]}]},{"title":"Chest Pain, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.10"},{"groupId":"OG001","value":"-0.08","spread":"0.99"},{"groupId":"OG002","value":"-0.16","spread":"1.09"}]}]},{"title":"Chest Pain, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.08"},{"groupId":"OG001","value":"-0.13","spread":"0.99"},{"groupId":"OG002","value":"-0.20","spread":"1.02"}]}]},{"title":"Chest Pain, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"1.12"},{"groupId":"OG001","value":"-0.18","spread":"0.92"},{"groupId":"OG002","value":"-0.14","spread":"1.16"}]}]},{"title":"Chest Pain, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.12"},{"groupId":"OG001","value":"-0.17","spread":"1.02"},{"groupId":"OG002","value":"-0.17","spread":"1.09"}]}]},{"title":"Chest Pain, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"1.00"},{"groupId":"OG001","value":"-0.19","spread":"0.97"},{"groupId":"OG002","value":"-0.21","spread":"1.10"}]}]},{"title":"Chest Pain, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.09"},{"groupId":"OG001","value":"-0.16","spread":"1.00"},{"groupId":"OG002","value":"-0.08","spread":"1.19"}]}]},{"title":"Chest Pain, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.08"},{"groupId":"OG001","value":"-0.24","spread":"0.91"},{"groupId":"OG002","value":"-0.09","spread":"1.16"}]}]},{"title":"Chest Pain, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"1.05"},{"groupId":"OG001","value":"-0.21","spread":"1.01"},{"groupId":"OG002","value":"-0.30","spread":"1.05"}]}]},{"title":"Chest Pain, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"144"},{"groupId":"OG002","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"1.24"},{"groupId":"OG001","value":"-0.22","spread":"1.02"},{"groupId":"OG002","value":"-0.17","spread":"1.10"}]}]},{"title":"Chest Pain, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"1.18"},{"groupId":"OG001","value":"-0.24","spread":"0.88"},{"groupId":"OG002","value":"-0.15","spread":"1.13"}]}]},{"title":"Chest Pain, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"1.19"},{"groupId":"OG001","value":"-0.28","spread":"0.99"},{"groupId":"OG002","value":"-0.17","spread":"1.00"}]}]},{"title":"Chest Pain, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.10"},{"groupId":"OG001","value":"-0.14","spread":"1.00"},{"groupId":"OG002","value":"-0.23","spread":"1.10"}]}]},{"title":"Chest Pain, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"1.11"},{"groupId":"OG001","value":"-0.17","spread":"0.99"},{"groupId":"OG002","value":"-0.24","spread":"1.10"}]}]},{"title":"Chest Pain, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.08"},{"groupId":"OG001","value":"-0.13","spread":"0.99"},{"groupId":"OG002","value":"-0.17","spread":"1.09"}]}]},{"title":"Chest Pain, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.09"},{"groupId":"OG001","value":"-0.10","spread":"0.99"},{"groupId":"OG002","value":"-0.16","spread":"1.07"}]}]},{"title":"Chest Pain, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"1.07"},{"groupId":"OG001","value":"-0.15","spread":"0.94"},{"groupId":"OG002","value":"-0.17","spread":"1.13"}]}]},{"title":"Chest Pain, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"1.02"},{"groupId":"OG001","value":"-0.07","spread":"1.02"},{"groupId":"OG002","value":"-0.18","spread":"1.14"}]}]},{"title":"Chest Pain, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.18"},{"groupId":"OG001","value":"-0.08","spread":"1.01"},{"groupId":"OG002","value":"-0.14","spread":"1.16"}]}]},{"title":"Chest Pain, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.16"},{"groupId":"OG001","value":"0.04","spread":"0.96"},{"groupId":"OG002","value":"-0.10","spread":"1.07"}]}]},{"title":"Chest Pain, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"1.15"},{"groupId":"OG001","value":"-0.15","spread":"0.97"},{"groupId":"OG002","value":"-0.17","spread":"1.14"}]}]},{"title":"Chest Pain, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.24"},{"groupId":"OG001","value":"-0.17","spread":"1.06"},{"groupId":"OG002","value":"-0.20","spread":"1.10"}]}]},{"title":"Chest Pain, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.20"},{"groupId":"OG001","value":"-0.06","spread":"1.08"},{"groupId":"OG002","value":"-0.11","spread":"1.09"}]}]},{"title":"Chest Pain, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.29"},{"groupId":"OG001","value":"-0.17","spread":"1.03"},{"groupId":"OG002","value":"0.04","spread":"1.14"}]}]},{"title":"Chest Pain, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"1.27"},{"groupId":"OG001","value":"-0.12","spread":"1.09"},{"groupId":"OG002","value":"-0.19","spread":"1.24"}]}]},{"title":"Chest Pain, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"1.23"},{"groupId":"OG001","value":"-0.11","spread":"0.96"},{"groupId":"OG002","value":"-0.18","spread":"1.11"}]}]},{"title":"Chest Pain, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.36"},{"groupId":"OG001","value":"-0.21","spread":"1.02"},{"groupId":"OG002","value":"-0.08","spread":"1.09"}]}]},{"title":"Chest Pain, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"1.25"},{"groupId":"OG001","value":"-0.16","spread":"0.99"},{"groupId":"OG002","value":"-0.15","spread":"1.08"}]}]},{"title":"Chest Pain, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.16"},{"groupId":"OG001","value":"-0.15","spread":"0.88"},{"groupId":"OG002","value":"-0.16","spread":"1.01"}]}]},{"title":"Chest Pain, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.35"},{"groupId":"OG001","value":"-0.20","spread":"0.97"},{"groupId":"OG002","value":"-0.10","spread":"1.09"}]}]},{"title":"Chest Pain, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.42"},{"groupId":"OG001","value":"-0.04","spread":"0.89"},{"groupId":"OG002","value":"0.02","spread":"1.16"}]}]},{"title":"Chest Pain, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"1.31"},{"groupId":"OG001","value":"-0.14","spread":"0.88"},{"groupId":"OG002","value":"-0.19","spread":"1.09"}]}]},{"title":"Chest Pain, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.34"},{"groupId":"OG001","value":"-0.06","spread":"0.88"},{"groupId":"OG002","value":"-0.06","spread":"1.12"}]}]},{"title":"Chest Pain, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.37"},{"groupId":"OG001","value":"0.05","spread":"1.06"},{"groupId":"OG002","value":"-0.08","spread":"1.08"}]}]},{"title":"Chest Pain, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.30"},{"groupId":"OG001","value":"-0.09","spread":"0.97"},{"groupId":"OG002","value":"-0.14","spread":"1.13"}]}]},{"title":"Chest Pain, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"1.53"},{"groupId":"OG001","value":"-0.18","spread":"0.96"},{"groupId":"OG002","value":"-0.13","spread":"1.13"}]}]},{"title":"Chest Pain, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"1.31"},{"groupId":"OG001","value":"-0.11","spread":"0.85"},{"groupId":"OG002","value":"-0.06","spread":"1.01"}]}]},{"title":"Chest Pain, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"1.21"},{"groupId":"OG001","value":"-0.14","spread":"0.92"},{"groupId":"OG002","value":"-0.13","spread":"1.05"}]}]},{"title":"Chest Pain, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"1.50"},{"groupId":"OG001","value":"-0.05","spread":"0.94"},{"groupId":"OG002","value":"-0.11","spread":"1.02"}]}]},{"title":"Chest Pain, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"1.59"},{"groupId":"OG001","value":"-0.08","spread":"0.99"},{"groupId":"OG002","value":"0.05","spread":"1.13"}]}]},{"title":"Chest Pain, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.52"},{"groupId":"OG001","value":"-0.25","spread":"0.99"},{"groupId":"OG002","value":"-0.10","spread":"1.07"}]}]},{"title":"Chest Pain, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.70"},{"groupId":"OG001","value":"-0.21","spread":"0.97"},{"groupId":"OG002","value":"-0.05","spread":"1.20"}]}]},{"title":"Chest Pain, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.39"},{"groupId":"OG001","value":"-0.16","spread":"1.04"},{"groupId":"OG002","value":"-0.07","spread":"1.33"}]}]},{"title":"Chest Pain, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"1.29"},{"groupId":"OG001","value":"-0.16","spread":"0.99"},{"groupId":"OG002","value":"0.04","spread":"1.29"}]}]},{"title":"Chest Pain, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.53"},{"groupId":"OG001","value":"-0.17","spread":"0.97"},{"groupId":"OG002","value":"0.00","spread":"1.32"}]}]},{"title":"Chest Pain, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"1.59"},{"groupId":"OG001","value":"-0.24","spread":"1.05"},{"groupId":"OG002","value":"-0.09","spread":"1.31"}]}]},{"title":"Chest Pain, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.73"},{"groupId":"OG001","value":"-0.17","spread":"0.98"},{"groupId":"OG002","value":"-0.14","spread":"1.36"}]}]},{"title":"Chest Pain, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"1.39"},{"groupId":"OG001","value":"-0.16","spread":"1.07"},{"groupId":"OG002","value":"-0.19","spread":"1.24"}]}]},{"title":"Chest Pain, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.30"},{"groupId":"OG001","value":"-0.09","spread":"0.98"},{"groupId":"OG002","value":"0.02","spread":"1.30"}]}]},{"title":"Chest Pain, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"1.27"},{"groupId":"OG001","value":"-0.12","spread":"0.95"},{"groupId":"OG002","value":"-0.20","spread":"1.22"}]}]},{"title":"Chest Pain, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.17"},{"groupId":"OG001","value":"-0.18","spread":"0.92"},{"groupId":"OG002","value":"-0.24","spread":"1.34"}]}]},{"title":"Chest Pain, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"1.37"},{"groupId":"OG001","value":"-0.11","spread":"0.79"},{"groupId":"OG002","value":"-0.15","spread":"1.19"}]}]},{"title":"Chest Pain, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.39"},{"groupId":"OG001","value":"-0.22","spread":"0.91"},{"groupId":"OG002","value":"-0.08","spread":"1.36"}]}]},{"title":"Chest Pain, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.46"},{"groupId":"OG001","value":"-0.22","spread":"0.95"},{"groupId":"OG002","value":"-0.27","spread":"1.22"}]}]},{"title":"Chest Pain, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"1.25"},{"groupId":"OG001","value":"-0.22","spread":"0.86"},{"groupId":"OG002","value":"-0.24","spread":"1.12"}]}]},{"title":"Chest Pain, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.32"},{"groupId":"OG001","value":"-0.20","spread":"1.01"},{"groupId":"OG002","value":"-0.28","spread":"1.17"}]}]},{"title":"Chest Pain, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"1.59"},{"groupId":"OG001","value":"-0.27","spread":"0.97"},{"groupId":"OG002","value":"-0.26","spread":"1.22"}]}]},{"title":"Chest Pain, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"1.29"},{"groupId":"OG001","value":"-0.23","spread":"0.83"},{"groupId":"OG002","value":"-0.34","spread":"1.23"}]}]},{"title":"Chest Pain, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.34"},{"groupId":"OG001","value":"-0.03","spread":"1.00"},{"groupId":"OG002","value":"-0.36","spread":"0.96"}]}]},{"title":"Chest Pain, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"1.21"},{"groupId":"OG001","value":"-0.12","spread":"0.92"},{"groupId":"OG002","value":"-0.55","spread":"1.13"}]}]},{"title":"Chest Pain, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.49"},{"groupId":"OG001","value":"-0.13","spread":"0.99"},{"groupId":"OG002","value":"-0.42","spread":"1.33"}]}]},{"title":"Chest Pain, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.37"},{"groupId":"OG001","value":"-0.13","spread":"0.95"},{"groupId":"OG002","value":"-0.25","spread":"1.21"}]}]},{"title":"Chest Pain, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"1.53"},{"groupId":"OG001","value":"0.00","spread":"1.26"},{"groupId":"OG002","value":"-0.47","spread":"1.18"}]}]},{"title":"Chest Pain, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.27"},{"groupId":"OG001","value":"-0.08","spread":"1.04"},{"groupId":"OG002","value":"-0.43","spread":"1.27"}]}]},{"title":"Chest Pain, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.77"},{"groupId":"OG001","value":"-0.09","spread":"1.02"},{"groupId":"OG002","value":"-0.53","spread":"1.23"}]}]},{"title":"Chest Pain, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.60"},{"groupId":"OG001","value":"-0.15","spread":"1.08"},{"groupId":"OG002","value":"-0.03","spread":"1.14"}]}]},{"title":"Chest Pain, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.79"},{"groupId":"OG001","value":"-0.06","spread":"0.97"},{"groupId":"OG002","value":"-0.32","spread":"1.08"}]}]},{"title":"Chest Pain, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.72"},{"groupId":"OG001","value":"-0.13","spread":"0.91"},{"groupId":"OG002","value":"-0.43","spread":"1.22"}]}]},{"title":"Chest Pain, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.70"},{"groupId":"OG001","value":"-0.20","spread":"0.94"},{"groupId":"OG002","value":"-0.14","spread":"1.00"}]}]},{"title":"Chest Pain, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"1.53"},{"groupId":"OG001","value":"-0.02","spread":"1.09"},{"groupId":"OG002","value":"-0.08","spread":"1.27"}]}]},{"title":"Chest Pain, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.62"},{"groupId":"OG001","value":"-0.10","spread":"1.14"},{"groupId":"OG002","value":"-0.38","spread":"1.21"}]}]},{"title":"Chest Pain, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.70"},{"groupId":"OG001","value":"-0.17","spread":"0.89"},{"groupId":"OG002","value":"-0.21","spread":"1.18"}]}]},{"title":"Chest Pain, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.76"},{"groupId":"OG001","value":"-0.02","spread":"1.03"},{"groupId":"OG002","value":"-0.21","spread":"1.25"}]}]},{"title":"Chest Pain, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.76"},{"groupId":"OG001","value":"0.00","spread":"1.15"},{"groupId":"OG002","value":"-0.05","spread":"1.21"}]}]},{"title":"Chest Pain, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"1.62"},{"groupId":"OG001","value":"-0.11","spread":"1.11"},{"groupId":"OG002","value":"0.00","spread":"1.02"}]}]},{"title":"Chest Pain, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.72"},{"groupId":"OG001","value":"-0.13","spread":"0.86"},{"groupId":"OG002","value":"0.17","spread":"0.94"}]}]},{"title":"Chest Pain, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"1.65"},{"groupId":"OG001","value":"-0.35","spread":"0.99"},{"groupId":"OG002","value":"0.09","spread":"1.14"}]}]},{"title":"Chest Pain, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.70"},{"groupId":"OG001","value":"-0.25","spread":"0.90"},{"groupId":"OG002","value":"0.22","spread":"0.97"}]}]},{"title":"Chest Pain, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"1.62"},{"groupId":"OG001","value":"-0.31","spread":"1.03"},{"groupId":"OG002","value":"0.22","spread":"1.12"}]}]},{"title":"Chest Pain, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.77"},{"groupId":"OG001","value":"-0.32","spread":"1.03"},{"groupId":"OG002","value":"-0.05","spread":"1.01"}]}]},{"title":"Chest Pain, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.84"},{"groupId":"OG001","value":"-0.33","spread":"1.08"},{"groupId":"OG002","value":"0.35","spread":"1.00"}]}]},{"title":"Chest Pain, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"1.31"},{"groupId":"OG001","value":"-0.35","spread":"1.03"},{"groupId":"OG002","value":"0.30","spread":"1.14"}]}]},{"title":"Chest Pain, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"1.53"},{"groupId":"OG001","value":"-0.37","spread":"0.95"},{"groupId":"OG002","value":"0.33","spread":"1.37"}]}]},{"title":"Chest Pain, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.73"},{"groupId":"OG001","value":"-0.25","spread":"1.10"},{"groupId":"OG002","value":"0.13","spread":"0.99"}]}]},{"title":"Chest Pain, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"1.44"},{"groupId":"OG001","value":"-0.20","spread":"1.22"},{"groupId":"OG002","value":"0.00","spread":"1.00"}]}]},{"title":"Chest Pain, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.08"},{"groupId":"OG001","value":"-0.14","spread":"1.08"},{"groupId":"OG002","value":"-0.29","spread":"1.25"}]}]},{"title":"Chest Pain, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.08"},{"groupId":"OG001","value":"-0.04","spread":"1.25"},{"groupId":"OG002","value":"0.00","spread":"1.29"}]}]},{"title":"Chest Pain, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.61"},{"groupId":"OG001","value":"-0.42","spread":"1.13"},{"groupId":"OG002","value":"0.14","spread":"1.07"}]}]},{"title":"Chest Pain, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"1.44"},{"groupId":"OG001","value":"-0.15","spread":"1.20"},{"groupId":"OG002","value":"0.19","spread":"1.25"}]}]},{"title":"Chest Pain, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"2.12"},{"groupId":"OG001","value":"0.00","spread":"1.24"},{"groupId":"OG002","value":"-0.05","spread":"1.01"}]}]},{"title":"Chest Pain, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.08"},{"groupId":"OG001","value":"-0.23","spread":"1.35"},{"groupId":"OG002","value":"0.00","spread":"1.20"}]}]},{"title":"Chest Pain, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.08"},{"groupId":"OG001","value":"0.14","spread":"1.19"},{"groupId":"OG002","value":"0.25","spread":"1.00"}]}]},{"title":"Chest Pain, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.61"},{"groupId":"OG001","value":"0.09","spread":"1.53"},{"groupId":"OG002","value":"0.19","spread":"0.92"}]}]},{"title":"Chest Pain, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.61"},{"groupId":"OG001","value":"-0.18","spread":"1.54"},{"groupId":"OG002","value":"-0.11","spread":"1.17"}]}]},{"title":"Chest Pain, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"2.02"},{"groupId":"OG001","value":"0.05","spread":"1.48"},{"groupId":"OG002","value":"0.00","spread":"1.00"}]}]},{"title":"Chest Pain, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"2.08"},{"groupId":"OG001","value":"0.00","spread":"1.53"},{"groupId":"OG002","value":"0.07","spread":"1.02"}]}]},{"title":"Chest Pain, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"1.77"},{"groupId":"OG001","value":"-0.15","spread":"1.43"},{"groupId":"OG002","value":"0.00","spread":"1.20"}]}]},{"title":"Chest Pain, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.61"},{"groupId":"OG001","value":"-0.10","spread":"1.54"},{"groupId":"OG002","value":"0.21","spread":"0.99"}]}]},{"title":"Chest Pain, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.32"},{"groupId":"OG001","value":"-0.25","spread":"0.88"},{"groupId":"OG002","value":"0.08","spread":"1.11"}]}]},{"title":"Chest Pain, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.56","spread":"1.04"},{"groupId":"OG002","value":"0.17","spread":"1.17"}]}]},{"title":"Chest Pain, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.56","spread":"1.05"},{"groupId":"OG002","value":"0.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.50","spread":"0.84"},{"groupId":"OG002","value":"0.00","spread":"1.10"}]}]},{"title":"Chest Pain, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"-0.72","spread":"1.06"},{"groupId":"OG002","value":"-0.40","spread":"1.14"}]}]},{"title":"Chest Pain, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.57","spread":"1.17"},{"groupId":"OG002","value":"-0.50","spread":"0.58"}]}]},{"title":"Chest Pain, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.30","spread":"1.25"},{"groupId":"OG002","value":"-0.38","spread":"0.75"}]}]},{"title":"Chest Pain, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.90","spread":"1.24"},{"groupId":"OG002","value":"0.25","spread":"1.77"}]}]},{"title":"Chest Pain, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.71"},{"groupId":"OG001","value":"-0.50","spread":"1.32"},{"groupId":"OG002","value":"-0.38","spread":"1.11"}]}]},{"title":"Chest Pain, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.25","spread":"1.26"},{"groupId":"OG002","value":"-0.38","spread":"0.48"}]}]},{"title":"Chest Pain, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.67","spread":"1.15"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"-0.50","spread":"1.00"},{"groupId":"OG002","value":"-0.67","spread":"0.58"}]}]},{"title":"Chest Pain, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.06"},{"groupId":"OG001","value":"-0.50","spread":"1.32"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.06"},{"groupId":"OG001","value":"-0.50","spread":"1.00"},{"groupId":"OG002","value":"-0.67","spread":"0.58"}]}]},{"title":"Chest Pain, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.67","spread":"1.15"},{"groupId":"OG002","value":"-0.67","spread":"0.58"}]}]},{"title":"Chest Pain, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.06"},{"groupId":"OG001","value":"-1.00","spread":"1.41"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00","spread":"0.00"}]}]},{"title":"Chest Pain, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Chest Pain, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"},{"groupId":"OG002","value":"-0.50"}]}]},{"title":"Chest Pain, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-0.50"}]}]},{"title":"Chest Pain, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-0.50"}]}]},{"title":"Chest Pain, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Chest Pain, Time of First Pd","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.13"},{"groupId":"OG001","value":"0.10","spread":"1.12"},{"groupId":"OG002","value":"-0.11","spread":"1.21"}]}]},{"title":"Chest Pain, Time of Last Tx Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.06"},{"groupId":"OG001","value":"0.01","spread":"1.09"},{"groupId":"OG002","value":"0.05","spread":"1.14"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.30"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"1.23"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"1.13"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"1.15"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"1.34"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.99"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.58"}]}]},{"title":"Chest Pain, Survival Follow-Up Month 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"1.06"}]}]},{"title":"Cough, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.78"},{"groupId":"OG001","value":"0.03","spread":"0.82"},{"groupId":"OG002","value":"-0.02","spread":"0.74"}]}]},{"title":"Cough, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.91"},{"groupId":"OG001","value":"0.00","spread":"0.90"},{"groupId":"OG002","value":"0.17","spread":"0.87"}]}]},{"title":"Cough, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.90"},{"groupId":"OG001","value":"-0.10","spread":"1.03"},{"groupId":"OG002","value":"-0.08","spread":"0.95"}]}]},{"title":"Cough, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.92"},{"groupId":"OG001","value":"-0.16","spread":"1.04"},{"groupId":"OG002","value":"-0.33","spread":"1.07"}]}]},{"title":"Cough, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.02"},{"groupId":"OG001","value":"-0.24","spread":"1.08"},{"groupId":"OG002","value":"-0.19","spread":"1.13"}]}]},{"title":"Cough, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.05"},{"groupId":"OG001","value":"-0.22","spread":"1.01"},{"groupId":"OG002","value":"-0.35","spread":"1.11"}]}]},{"title":"Cough, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.06"},{"groupId":"OG001","value":"-0.27","spread":"1.07"},{"groupId":"OG002","value":"-0.47","spread":"1.11"}]}]},{"title":"Cough, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"1.11"},{"groupId":"OG001","value":"-0.26","spread":"0.97"},{"groupId":"OG002","value":"-0.36","spread":"1.09"}]}]},{"title":"Cough, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"1.16"},{"groupId":"OG001","value":"-0.27","spread":"1.01"},{"groupId":"OG002","value":"-0.34","spread":"1.09"}]}]},{"title":"Cough, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.02"},{"groupId":"OG001","value":"-0.28","spread":"1.09"},{"groupId":"OG002","value":"-0.42","spread":"1.08"}]}]},{"title":"Cough, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.98"},{"groupId":"OG001","value":"-0.27","spread":"1.14"},{"groupId":"OG002","value":"-0.50","spread":"1.06"}]}]},{"title":"Cough, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"1.08"},{"groupId":"OG001","value":"-0.25","spread":"1.13"},{"groupId":"OG002","value":"-0.46","spread":"1.06"}]}]},{"title":"Cough, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"144"},{"groupId":"OG002","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"1.14"},{"groupId":"OG001","value":"-0.28","spread":"1.17"},{"groupId":"OG002","value":"-0.46","spread":"1.10"}]}]},{"title":"Cough, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"1.09"},{"groupId":"OG001","value":"-0.29","spread":"1.13"},{"groupId":"OG002","value":"-0.50","spread":"1.16"}]}]},{"title":"Cough, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"1.11"},{"groupId":"OG001","value":"-0.23","spread":"1.03"},{"groupId":"OG002","value":"-0.47","spread":"1.18"}]}]},{"title":"Cough, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"1.19"},{"groupId":"OG001","value":"-0.18","spread":"1.14"},{"groupId":"OG002","value":"-0.52","spread":"1.25"}]}]},{"title":"Cough, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.08"},{"groupId":"OG001","value":"-0.21","spread":"1.06"},{"groupId":"OG002","value":"-0.48","spread":"1.16"}]}]},{"title":"Cough, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"1.09"},{"groupId":"OG001","value":"-0.34","spread":"1.12"},{"groupId":"OG002","value":"-0.48","spread":"1.05"}]}]},{"title":"Cough, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.05"},{"groupId":"OG001","value":"-0.29","spread":"1.12"},{"groupId":"OG002","value":"-0.37","spread":"1.04"}]}]},{"title":"Cough, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.09"},{"groupId":"OG001","value":"-0.24","spread":"1.00"},{"groupId":"OG002","value":"-0.51","spread":"1.15"}]}]},{"title":"Cough, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"1.01"},{"groupId":"OG001","value":"-0.26","spread":"1.06"},{"groupId":"OG002","value":"-0.46","spread":"1.09"}]}]},{"title":"Cough, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"1.13"},{"groupId":"OG001","value":"-0.27","spread":"1.09"},{"groupId":"OG002","value":"-0.44","spread":"1.11"}]}]},{"title":"Cough, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"1.19"},{"groupId":"OG001","value":"-0.30","spread":"1.07"},{"groupId":"OG002","value":"-0.45","spread":"1.17"}]}]},{"title":"Cough, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.14"},{"groupId":"OG001","value":"-0.33","spread":"1.00"},{"groupId":"OG002","value":"-0.46","spread":"1.11"}]}]},{"title":"Cough, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.18"},{"groupId":"OG001","value":"-0.31","spread":"1.09"},{"groupId":"OG002","value":"-0.52","spread":"1.06"}]}]},{"title":"Cough, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"1.08"},{"groupId":"OG001","value":"-0.32","spread":"1.09"},{"groupId":"OG002","value":"-0.54","spread":"1.24"}]}]},{"title":"Cough, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.11"},{"groupId":"OG001","value":"-0.39","spread":"1.10"},{"groupId":"OG002","value":"-0.31","spread":"1.20"}]}]},{"title":"Cough, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"1.10"},{"groupId":"OG001","value":"-0.36","spread":"1.07"},{"groupId":"OG002","value":"-0.52","spread":"1.21"}]}]},{"title":"Cough, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"1.15"},{"groupId":"OG001","value":"-0.33","spread":"1.06"},{"groupId":"OG002","value":"-0.48","spread":"1.13"}]}]},{"title":"Cough, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.15"},{"groupId":"OG001","value":"-0.31","spread":"1.02"},{"groupId":"OG002","value":"-0.54","spread":"1.14"}]}]},{"title":"Cough, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.14"},{"groupId":"OG001","value":"-0.34","spread":"1.11"},{"groupId":"OG002","value":"-0.49","spread":"1.10"}]}]},{"title":"Cough, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.98"},{"groupId":"OG001","value":"-0.41","spread":"1.02"},{"groupId":"OG002","value":"-0.53","spread":"1.04"}]}]},{"title":"Cough, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"1.11"},{"groupId":"OG001","value":"-0.35","spread":"0.97"},{"groupId":"OG002","value":"-0.53","spread":"1.13"}]}]},{"title":"Cough, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.93"},{"groupId":"OG001","value":"-0.34","spread":"0.84"},{"groupId":"OG002","value":"-0.41","spread":"1.14"}]}]},{"title":"Cough, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"1.01"},{"groupId":"OG001","value":"-0.38","spread":"0.91"},{"groupId":"OG002","value":"-0.47","spread":"1.05"}]}]},{"title":"Cough, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.93"},{"groupId":"OG001","value":"-0.39","spread":"0.96"},{"groupId":"OG002","value":"-0.43","spread":"0.99"}]}]},{"title":"Cough, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.11"},{"groupId":"OG001","value":"-0.22","spread":"0.94"},{"groupId":"OG002","value":"-0.54","spread":"1.12"}]}]},{"title":"Cough, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"1.09"},{"groupId":"OG001","value":"-0.36","spread":"0.97"},{"groupId":"OG002","value":"-0.45","spread":"1.16"}]}]},{"title":"Cough, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.05"},{"groupId":"OG001","value":"-0.46","spread":"1.05"},{"groupId":"OG002","value":"-0.50","spread":"1.06"}]}]},{"title":"Cough, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"1.12"},{"groupId":"OG001","value":"-0.39","spread":"1.04"},{"groupId":"OG002","value":"-0.47","spread":"1.02"}]}]},{"title":"Cough, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"1.21"},{"groupId":"OG001","value":"-0.43","spread":"1.10"},{"groupId":"OG002","value":"-0.58","spread":"1.06"}]}]},{"title":"Cough, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"1.16"},{"groupId":"OG001","value":"-0.41","spread":"1.05"},{"groupId":"OG002","value":"-0.68","spread":"1.05"}]}]},{"title":"Cough, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.87"},{"groupId":"OG001","value":"-0.38","spread":"1.04"},{"groupId":"OG002","value":"-0.45","spread":"0.99"}]}]},{"title":"Cough, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"1.24"},{"groupId":"OG001","value":"-0.48","spread":"1.21"},{"groupId":"OG002","value":"-0.56","spread":"1.09"}]}]},{"title":"Cough, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"1.24"},{"groupId":"OG001","value":"-0.32","spread":"1.11"},{"groupId":"OG002","value":"-0.69","spread":"1.00"}]}]},{"title":"Cough, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.95"},{"groupId":"OG001","value":"-0.38","spread":"1.11"},{"groupId":"OG002","value":"-0.67","spread":"1.10"}]}]},{"title":"Cough, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"1.15"},{"groupId":"OG001","value":"-0.38","spread":"1.13"},{"groupId":"OG002","value":"-0.54","spread":"0.97"}]}]},{"title":"Cough, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.22"},{"groupId":"OG001","value":"-0.41","spread":"1.09"},{"groupId":"OG002","value":"-0.55","spread":"1.09"}]}]},{"title":"Cough, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"1.04"},{"groupId":"OG001","value":"-0.44","spread":"1.10"},{"groupId":"OG002","value":"-0.63","spread":"1.06"}]}]},{"title":"Cough, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.98"},{"groupId":"OG001","value":"-0.29","spread":"1.16"},{"groupId":"OG002","value":"-0.72","spread":"1.07"}]}]},{"title":"Cough, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.88"},{"groupId":"OG001","value":"-0.22","spread":"1.20"},{"groupId":"OG002","value":"-0.69","spread":"1.11"}]}]},{"title":"Cough, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.79"},{"groupId":"OG001","value":"-0.33","spread":"1.19"},{"groupId":"OG002","value":"-0.64","spread":"1.03"}]}]},{"title":"Cough, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.78"},{"groupId":"OG001","value":"-0.28","spread":"1.14"},{"groupId":"OG002","value":"-0.53","spread":"1.19"}]}]},{"title":"Cough, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.89"},{"groupId":"OG001","value":"-0.45","spread":"1.06"},{"groupId":"OG002","value":"-0.63","spread":"1.23"}]}]},{"title":"Cough, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"1.05"},{"groupId":"OG001","value":"-0.38","spread":"1.12"},{"groupId":"OG002","value":"-0.68","spread":"1.17"}]}]},{"title":"Cough, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"1.05"},{"groupId":"OG001","value":"-0.46","spread":"1.13"},{"groupId":"OG002","value":"-0.51","spread":"1.07"}]}]},{"title":"Cough, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.81"},{"groupId":"OG001","value":"-0.36","spread":"1.25"},{"groupId":"OG002","value":"-0.74","spread":"1.10"}]}]},{"title":"Cough, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.94"},{"groupId":"OG001","value":"-0.51","spread":"1.14"},{"groupId":"OG002","value":"-0.67","spread":"1.06"}]}]},{"title":"Cough, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.81"},{"groupId":"OG001","value":"-0.45","spread":"1.19"},{"groupId":"OG002","value":"-0.81","spread":"1.12"}]}]},{"title":"Cough, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.71"},{"groupId":"OG001","value":"-0.41","spread":"1.26"},{"groupId":"OG002","value":"-0.69","spread":"1.04"}]}]},{"title":"Cough, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.97"},{"groupId":"OG001","value":"-0.38","spread":"1.27"},{"groupId":"OG002","value":"-0.84","spread":"1.08"}]}]},{"title":"Cough, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.86"},{"groupId":"OG001","value":"-0.29","spread":"1.29"},{"groupId":"OG002","value":"-0.78","spread":"1.04"}]}]},{"title":"Cough, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.70"},{"groupId":"OG001","value":"-0.30","spread":"1.09"},{"groupId":"OG002","value":"-0.82","spread":"0.99"}]}]},{"title":"Cough, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"1.16"},{"groupId":"OG001","value":"-0.27","spread":"1.21"},{"groupId":"OG002","value":"-0.81","spread":"0.93"}]}]},{"title":"Cough, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.97"},{"groupId":"OG001","value":"-0.28","spread":"1.26"},{"groupId":"OG002","value":"-0.70","spread":"1.15"}]}]},{"title":"Cough, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.86"},{"groupId":"OG001","value":"-0.30","spread":"1.22"},{"groupId":"OG002","value":"-0.82","spread":"1.15"}]}]},{"title":"Cough, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.67"},{"groupId":"OG001","value":"-0.44","spread":"1.29"},{"groupId":"OG002","value":"-0.78","spread":"1.09"}]}]},{"title":"Cough, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.95"},{"groupId":"OG001","value":"-0.21","spread":"1.36"},{"groupId":"OG002","value":"-0.66","spread":"1.17"}]}]},{"title":"Cough, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.91"},{"groupId":"OG001","value":"-0.26","spread":"1.29"},{"groupId":"OG002","value":"-0.78","spread":"1.14"}]}]},{"title":"Cough, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.91"},{"groupId":"OG001","value":"-0.28","spread":"1.13"},{"groupId":"OG002","value":"-0.92","spread":"1.18"}]}]},{"title":"Cough, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.21"},{"groupId":"OG001","value":"-0.15","spread":"1.01"},{"groupId":"OG002","value":"-0.90","spread":"1.21"}]}]},{"title":"Cough, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.38"},{"groupId":"OG001","value":"-0.19","spread":"1.10"},{"groupId":"OG002","value":"-0.72","spread":"1.05"}]}]},{"title":"Cough, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.38"},{"groupId":"OG001","value":"-0.22","spread":"1.15"},{"groupId":"OG002","value":"-1.00","spread":"1.38"}]}]},{"title":"Cough, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.89"},{"groupId":"OG001","value":"-0.22","spread":"0.97"},{"groupId":"OG002","value":"-1.04","spread":"1.21"}]}]},{"title":"Cough, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.24"},{"groupId":"OG001","value":"-0.17","spread":"1.12"},{"groupId":"OG002","value":"-1.04","spread":"1.29"}]}]},{"title":"Cough, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.38"},{"groupId":"OG001","value":"0.07","spread":"1.16"},{"groupId":"OG002","value":"-1.18","spread":"1.12"}]}]},{"title":"Cough, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.29"},{"groupId":"OG001","value":"-0.18","spread":"1.29"},{"groupId":"OG002","value":"-0.60","spread":"1.05"}]}]},{"title":"Cough, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.26"},{"groupId":"OG001","value":"-0.30","spread":"1.08"},{"groupId":"OG002","value":"-0.86","spread":"1.12"}]}]},{"title":"Cough, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.38"},{"groupId":"OG001","value":"-0.04","spread":"1.04"},{"groupId":"OG002","value":"-0.61","spread":"1.41"}]}]},{"title":"Cough, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"1.07"},{"groupId":"OG001","value":"-0.45","spread":"1.17"},{"groupId":"OG002","value":"-0.95","spread":"1.13"}]}]},{"title":"Cough, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.02"},{"groupId":"OG001","value":"-0.31","spread":"1.14"},{"groupId":"OG002","value":"-0.72","spread":"1.25"}]}]},{"title":"Cough, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.17"},{"groupId":"OG001","value":"-0.33","spread":"1.06"},{"groupId":"OG002","value":"-0.44","spread":"1.13"}]}]},{"title":"Cough, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.44"},{"groupId":"OG001","value":"-0.39","spread":"1.06"},{"groupId":"OG002","value":"-1.00","spread":"1.20"}]}]},{"title":"Cough, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"1.30"},{"groupId":"OG001","value":"-0.10","spread":"1.28"},{"groupId":"OG002","value":"-0.90","spread":"1.26"}]}]},{"title":"Cough, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.58"},{"groupId":"OG001","value":"-0.24","spread":"1.13"},{"groupId":"OG002","value":"-0.60","spread":"1.60"}]}]},{"title":"Cough, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.58"},{"groupId":"OG001","value":"-0.27","spread":"1.28"},{"groupId":"OG002","value":"-0.42","spread":"1.32"}]}]},{"title":"Cough, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"0.00","spread":"1.30"},{"groupId":"OG002","value":"-0.94","spread":"1.35"}]}]},{"title":"Cough, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.76"},{"groupId":"OG001","value":"-0.37","spread":"1.19"},{"groupId":"OG002","value":"-1.29","spread":"1.41"}]}]},{"title":"Cough, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"-0.29","spread":"1.17"},{"groupId":"OG002","value":"-1.14","spread":"1.31"}]}]},{"title":"Cough, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.50"},{"groupId":"OG001","value":"-0.35","spread":"1.14"},{"groupId":"OG002","value":"-0.79","spread":"1.29"}]}]},{"title":"Cough, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.76"},{"groupId":"OG001","value":"-0.58","spread":"1.19"},{"groupId":"OG002","value":"-0.93","spread":"1.37"}]}]},{"title":"Cough, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.58"},{"groupId":"OG001","value":"-0.19","spread":"1.18"},{"groupId":"OG002","value":"-0.94","spread":"1.37"}]}]},{"title":"Cough, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.71"},{"groupId":"OG001","value":"-0.42","spread":"1.26"},{"groupId":"OG002","value":"-0.90","spread":"1.13"}]}]},{"title":"Cough, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"-0.41","spread":"1.26"},{"groupId":"OG002","value":"-0.88","spread":"1.25"}]}]},{"title":"Cough, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"0.00","spread":"1.28"},{"groupId":"OG002","value":"-0.81","spread":"1.31"}]}]},{"title":"Cough, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"-0.18","spread":"1.45"},{"groupId":"OG002","value":"-1.00","spread":"1.31"}]}]},{"title":"Cough, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.50"},{"groupId":"OG001","value":"-0.14","spread":"1.12"},{"groupId":"OG002","value":"-0.78","spread":"1.23"}]}]},{"title":"Cough, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.50"},{"groupId":"OG001","value":"-0.35","spread":"1.18"},{"groupId":"OG002","value":"-1.00","spread":"1.29"}]}]},{"title":"Cough, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"0.00","spread":"1.41"},{"groupId":"OG002","value":"-0.64","spread":"1.14"}]}]},{"title":"Cough, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.71"},{"groupId":"OG001","value":"-0.35","spread":"1.16"},{"groupId":"OG002","value":"-0.81","spread":"1.25"}]}]},{"title":"Cough, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.58"},{"groupId":"OG001","value":"-0.20","spread":"1.32"},{"groupId":"OG002","value":"-0.79","spread":"1.32"}]}]},{"title":"Cough, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.76"},{"groupId":"OG001","value":"0.00","spread":"1.30"},{"groupId":"OG002","value":"-0.75","spread":"1.44"}]}]},{"title":"Cough, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.56","spread":"1.07"},{"groupId":"OG002","value":"-0.67","spread":"1.44"}]}]},{"title":"Cough, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.38","spread":"1.19"},{"groupId":"OG002","value":"0.00","spread":"1.08"}]}]},{"title":"Cough, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"0.08","spread":"0.80"},{"groupId":"OG002","value":"-0.25","spread":"1.33"}]}]},{"title":"Cough, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.28","spread":"1.23"},{"groupId":"OG002","value":"-0.80","spread":"1.04"}]}]},{"title":"Cough, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.57","spread":"1.48"},{"groupId":"OG002","value":"-1.25","spread":"1.19"}]}]},{"title":"Cough, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.70","spread":"1.64"},{"groupId":"OG002","value":"-1.38","spread":"1.11"}]}]},{"title":"Cough, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.30","spread":"1.82"},{"groupId":"OG002","value":"-0.75","spread":"1.06"}]}]},{"title":"Cough, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"0.50","spread":"1.80"},{"groupId":"OG002","value":"-1.25","spread":"1.04"}]}]},{"title":"Cough, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"-0.13","spread":"1.93"},{"groupId":"OG002","value":"-1.25","spread":"1.04"}]}]},{"title":"Cough, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"0.17","spread":"1.44"},{"groupId":"OG002","value":"-1.75","spread":"0.35"}]}]},{"title":"Cough, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50"},{"groupId":"OG001","value":"0.13","spread":"1.75"},{"groupId":"OG002","value":"-1.17","spread":"1.04"}]}]},{"title":"Cough, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.50","spread":"1.80"},{"groupId":"OG002","value":"-1.50","spread":"0.71"}]}]},{"title":"Cough, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.00"},{"groupId":"OG001","value":"-0.88","spread":"1.31"},{"groupId":"OG002","value":"-1.00","spread":"1.00"}]}]},{"title":"Cough, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"-0.50","spread":"1.32"},{"groupId":"OG002","value":"-1.33","spread":"1.15"}]}]},{"title":"Cough, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"-0.25","spread":"1.77"},{"groupId":"OG002","value":"-1.50","spread":"0.71"}]}]},{"title":"Cough, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50"},{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-1.50","spread":"0.71"}]}]},{"title":"Cough, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-1.00","spread":"0.71"}]}]},{"title":"Cough, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-1.00","spread":"0.71"}]}]},{"title":"Cough, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-1.00","spread":"0.71"}]}]},{"title":"Cough, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-1.25","spread":"0.35"}]}]},{"title":"Cough, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00"},{"groupId":"OG002","value":"-2.00"}]}]},{"title":"Cough, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"},{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Cough, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-2.00"}]}]},{"title":"Cough, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Cough, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Cough, Time of First Pd","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"1.05"},{"groupId":"OG001","value":"-0.16","spread":"1.12"},{"groupId":"OG002","value":"-0.16","spread":"1.05"}]}]},{"title":"Cough, Time of Last Tx Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"1.10"},{"groupId":"OG001","value":"-0.24","spread":"1.09"},{"groupId":"OG002","value":"-0.21","spread":"1.13"}]}]},{"title":"Cough, Survival Follow-Up Month 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"1.13"}]}]},{"title":"Cough, Survival Follow-Up Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.04"}]}]},{"title":"Cough, Survival Follow-Up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.06"}]}]},{"title":"Cough, Survival Follow-Up Month 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"1.32"}]}]},{"title":"Cough, Survival Follow-Up Month 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"1.14"}]}]},{"title":"Cough, Survival Follow-Up Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.17"}]}]},{"title":"Cough, Survival Follow-Up Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.29"}]}]},{"title":"Cough, Survival Follow-Up Month 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"2.12"}]}]},{"title":"Dyspnoea, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.80"},{"groupId":"OG001","value":"0.11","spread":"0.76"},{"groupId":"OG002","value":"0.17","spread":"0.73"}]}]},{"title":"Dyspnoea, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.75"},{"groupId":"OG001","value":"0.11","spread":"0.86"},{"groupId":"OG002","value":"0.27","spread":"0.88"}]}]},{"title":"Dyspnoea, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.83"},{"groupId":"OG001","value":"0.16","spread":"0.81"},{"groupId":"OG002","value":"0.30","spread":"0.89"}]}]},{"title":"Dyspnoea, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.89"},{"groupId":"OG001","value":"0.16","spread":"0.83"},{"groupId":"OG002","value":"0.26","spread":"0.89"}]}]},{"title":"Dyspnoea, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.89"},{"groupId":"OG001","value":"0.25","spread":"0.88"},{"groupId":"OG002","value":"0.31","spread":"0.85"}]}]},{"title":"Dyspnoea, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.97"},{"groupId":"OG001","value":"0.23","spread":"0.83"},{"groupId":"OG002","value":"0.29","spread":"0.88"}]}]},{"title":"Dyspnoea, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"166"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.98"},{"groupId":"OG001","value":"0.25","spread":"0.91"},{"groupId":"OG002","value":"0.27","spread":"0.96"}]}]},{"title":"Dyspnoea, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.95"},{"groupId":"OG001","value":"0.29","spread":"0.91"},{"groupId":"OG002","value":"0.31","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.97"},{"groupId":"OG001","value":"0.26","spread":"0.85"},{"groupId":"OG002","value":"0.33","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.99"},{"groupId":"OG001","value":"0.34","spread":"0.94"},{"groupId":"OG002","value":"0.34","spread":"0.95"}]}]},{"title":"Dyspnoea, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.95"},{"groupId":"OG001","value":"0.31","spread":"0.91"},{"groupId":"OG002","value":"0.35","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.98"},{"groupId":"OG001","value":"0.41","spread":"1.01"},{"groupId":"OG002","value":"0.29","spread":"0.90"}]}]},{"title":"Dyspnoea, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"144"},{"groupId":"OG002","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"1.03"},{"groupId":"OG001","value":"0.32","spread":"0.92"},{"groupId":"OG002","value":"0.34","spread":"0.94"}]}]},{"title":"Dyspnoea, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.95"},{"groupId":"OG001","value":"0.29","spread":"0.92"},{"groupId":"OG002","value":"0.34","spread":"0.91"}]}]},{"title":"Dyspnoea, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.98"},{"groupId":"OG001","value":"0.32","spread":"0.92"},{"groupId":"OG002","value":"0.30","spread":"0.91"}]}]},{"title":"Dyspnoea, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"121"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.95"},{"groupId":"OG001","value":"0.32","spread":"0.93"},{"groupId":"OG002","value":"0.36","spread":"0.92"}]}]},{"title":"Dyspnoea, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.99"},{"groupId":"OG001","value":"0.25","spread":"0.90"},{"groupId":"OG002","value":"0.29","spread":"0.91"}]}]},{"title":"Dyspnoea, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.93"},{"groupId":"OG001","value":"0.28","spread":"0.93"},{"groupId":"OG002","value":"0.34","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.97"},{"groupId":"OG001","value":"0.28","spread":"0.98"},{"groupId":"OG002","value":"0.44","spread":"0.96"}]}]},{"title":"Dyspnoea, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.97"},{"groupId":"OG001","value":"0.28","spread":"0.93"},{"groupId":"OG002","value":"0.24","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.94"},{"groupId":"OG001","value":"0.23","spread":"0.98"},{"groupId":"OG002","value":"0.19","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"109"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.95"},{"groupId":"OG001","value":"0.25","spread":"0.96"},{"groupId":"OG002","value":"0.24","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.94"},{"groupId":"OG001","value":"0.30","spread":"0.99"},{"groupId":"OG002","value":"0.20","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.01"},{"groupId":"OG001","value":"0.20","spread":"0.91"},{"groupId":"OG002","value":"0.29","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"104"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.94"},{"groupId":"OG001","value":"0.18","spread":"0.95"},{"groupId":"OG002","value":"0.25","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.84"},{"groupId":"OG001","value":"0.31","spread":"0.96"},{"groupId":"OG002","value":"0.39","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.80"},{"groupId":"OG001","value":"0.21","spread":"0.95"},{"groupId":"OG002","value":"0.36","spread":"1.14"}]}]},{"title":"Dyspnoea, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"103"},{"groupId":"OG002","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.83"},{"groupId":"OG001","value":"0.17","spread":"0.86"},{"groupId":"OG002","value":"0.30","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.82"},{"groupId":"OG001","value":"0.19","spread":"0.96"},{"groupId":"OG002","value":"0.31","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.82"},{"groupId":"OG001","value":"0.12","spread":"0.94"},{"groupId":"OG002","value":"0.39","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"77"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.76"},{"groupId":"OG001","value":"0.18","spread":"0.96"},{"groupId":"OG002","value":"0.36","spread":"1.12"}]}]},{"title":"Dyspnoea, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.79"},{"groupId":"OG001","value":"0.09","spread":"0.84"},{"groupId":"OG002","value":"0.26","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.74"},{"groupId":"OG001","value":"0.02","spread":"0.85"},{"groupId":"OG002","value":"0.31","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.69"},{"groupId":"OG001","value":"0.05","spread":"0.76"},{"groupId":"OG002","value":"0.30","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.88"},{"groupId":"OG001","value":"0.04","spread":"0.82"},{"groupId":"OG002","value":"0.38","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.68"},{"groupId":"OG001","value":"0.11","spread":"0.82"},{"groupId":"OG002","value":"0.37","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.76"},{"groupId":"OG001","value":"0.16","spread":"0.92"},{"groupId":"OG002","value":"0.32","spread":"0.92"}]}]},{"title":"Dyspnoea, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.75"},{"groupId":"OG001","value":"0.10","spread":"0.78"},{"groupId":"OG002","value":"0.40","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.76"},{"groupId":"OG001","value":"0.04","spread":"0.87"},{"groupId":"OG002","value":"0.36","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.74"},{"groupId":"OG001","value":"0.24","spread":"0.92"},{"groupId":"OG002","value":"0.37","spread":"0.91"}]}]},{"title":"Dyspnoea, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.92"},{"groupId":"OG001","value":"0.13","spread":"0.84"},{"groupId":"OG002","value":"0.33","spread":"0.89"}]}]},{"title":"Dyspnoea, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.82"},{"groupId":"OG001","value":"0.05","spread":"0.81"},{"groupId":"OG002","value":"0.29","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.94"},{"groupId":"OG001","value":"0.16","spread":"0.76"},{"groupId":"OG002","value":"0.41","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.95"},{"groupId":"OG001","value":"0.11","spread":"0.88"},{"groupId":"OG002","value":"0.33","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"1.04"},{"groupId":"OG001","value":"0.20","spread":"0.84"},{"groupId":"OG002","value":"0.27","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.98"},{"groupId":"OG001","value":"0.08","spread":"0.78"},{"groupId":"OG002","value":"0.26","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.85"},{"groupId":"OG001","value":"0.06","spread":"0.80"},{"groupId":"OG002","value":"0.31","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.88"},{"groupId":"OG001","value":"0.14","spread":"0.85"},{"groupId":"OG002","value":"0.22","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.99"},{"groupId":"OG001","value":"0.06","spread":"0.78"},{"groupId":"OG002","value":"0.14","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"0.84"},{"groupId":"OG001","value":"0.10","spread":"0.85"},{"groupId":"OG002","value":"0.06","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.92"},{"groupId":"OG001","value":"0.08","spread":"0.78"},{"groupId":"OG002","value":"0.15","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.81"},{"groupId":"OG001","value":"0.11","spread":"0.86"},{"groupId":"OG002","value":"0.34","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.85"},{"groupId":"OG001","value":"0.11","spread":"0.89"},{"groupId":"OG002","value":"0.11","spread":"1.11"}]}]},{"title":"Dyspnoea, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.94"},{"groupId":"OG001","value":"0.11","spread":"0.80"},{"groupId":"OG002","value":"0.10","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"0.93"},{"groupId":"OG001","value":"0.15","spread":"0.85"},{"groupId":"OG002","value":"0.16","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"0.94"},{"groupId":"OG001","value":"0.14","spread":"0.95"},{"groupId":"OG002","value":"0.12","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.80"},{"groupId":"OG001","value":"0.12","spread":"0.90"},{"groupId":"OG002","value":"0.13","spread":"1.03"}]}]},{"title":"Dyspnoea, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.93"},{"groupId":"OG001","value":"0.02","spread":"0.98"},{"groupId":"OG002","value":"0.12","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"1.09"},{"groupId":"OG001","value":"0.11","spread":"1.00"},{"groupId":"OG002","value":"-0.03","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.86"},{"groupId":"OG001","value":"0.06","spread":"0.93"},{"groupId":"OG002","value":"0.02","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.91"},{"groupId":"OG001","value":"0.05","spread":"0.92"},{"groupId":"OG002","value":"-0.18","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.94"},{"groupId":"OG001","value":"0.01","spread":"0.96"},{"groupId":"OG002","value":"-0.04","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"1.14"},{"groupId":"OG001","value":"0.10","spread":"0.95"},{"groupId":"OG002","value":"-0.06","spread":"0.72"}]}]},{"title":"Dyspnoea, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.98"},{"groupId":"OG001","value":"0.07","spread":"1.08"},{"groupId":"OG002","value":"-0.22","spread":"0.74"}]}]},{"title":"Dyspnoea, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"1.06"},{"groupId":"OG001","value":"0.05","spread":"1.05"},{"groupId":"OG002","value":"-0.18","spread":"0.87"}]}]},{"title":"Dyspnoea, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.02"},{"groupId":"OG001","value":"0.04","spread":"1.07"},{"groupId":"OG002","value":"-0.18","spread":"0.85"}]}]},{"title":"Dyspnoea, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.95"},{"groupId":"OG001","value":"0.04","spread":"1.15"},{"groupId":"OG002","value":"-0.24","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.98"},{"groupId":"OG001","value":"0.01","spread":"1.07"},{"groupId":"OG002","value":"-0.11","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.59"},{"groupId":"OG001","value":"0.06","spread":"1.19"},{"groupId":"OG002","value":"-0.20","spread":"0.87"}]}]},{"title":"Dyspnoea, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.60"},{"groupId":"OG001","value":"0.16","spread":"1.08"},{"groupId":"OG002","value":"-0.18","spread":"0.94"}]}]},{"title":"Dyspnoea, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.91"},{"groupId":"OG001","value":"0.22","spread":"1.08"},{"groupId":"OG002","value":"-0.01","spread":"0.82"}]}]},{"title":"Dyspnoea, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.98"},{"groupId":"OG001","value":"0.25","spread":"1.16"},{"groupId":"OG002","value":"-0.06","spread":"0.79"}]}]},{"title":"Dyspnoea, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.07"},{"groupId":"OG001","value":"0.10","spread":"1.18"},{"groupId":"OG002","value":"-0.11","spread":"0.79"}]}]},{"title":"Dyspnoea, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.96"},{"groupId":"OG001","value":"0.10","spread":"1.15"},{"groupId":"OG002","value":"-0.17","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.99"},{"groupId":"OG001","value":"0.05","spread":"1.13"},{"groupId":"OG002","value":"-0.22","spread":"0.81"}]}]},{"title":"Dyspnoea, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.90"},{"groupId":"OG001","value":"0.25","spread":"1.33"},{"groupId":"OG002","value":"-0.13","spread":"0.90"}]}]},{"title":"Dyspnoea, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.95"},{"groupId":"OG001","value":"0.04","spread":"1.36"},{"groupId":"OG002","value":"0.12","spread":"0.76"}]}]},{"title":"Dyspnoea, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.94"},{"groupId":"OG001","value":"0.09","spread":"1.24"},{"groupId":"OG002","value":"-0.20","spread":"0.95"}]}]},{"title":"Dyspnoea, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.77"},{"groupId":"OG001","value":"0.16","spread":"1.29"},{"groupId":"OG002","value":"-0.13","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.78"},{"groupId":"OG001","value":"-0.13","spread":"1.17"},{"groupId":"OG002","value":"0.00","spread":"0.81"}]}]},{"title":"Dyspnoea, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.92"},{"groupId":"OG001","value":"-0.02","spread":"1.17"},{"groupId":"OG002","value":"-0.04","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.91"},{"groupId":"OG001","value":"-0.05","spread":"1.16"},{"groupId":"OG002","value":"0.00","spread":"0.90"}]}]},{"title":"Dyspnoea, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.69"},{"groupId":"OG001","value":"-0.08","spread":"1.26"},{"groupId":"OG002","value":"-0.40","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.59"},{"groupId":"OG001","value":"-0.17","spread":"1.23"},{"groupId":"OG002","value":"-0.22","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.50"},{"groupId":"OG001","value":"-0.16","spread":"1.11"},{"groupId":"OG002","value":"-0.16","spread":"1.03"}]}]},{"title":"Dyspnoea, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"1.45"},{"groupId":"OG001","value":"-0.23","spread":"1.12"},{"groupId":"OG002","value":"-0.17","spread":"1.26"}]}]},{"title":"Dyspnoea, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.40"},{"groupId":"OG001","value":"0.08","spread":"1.45"},{"groupId":"OG002","value":"-0.25","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.69"},{"groupId":"OG001","value":"-0.21","spread":"1.06"},{"groupId":"OG002","value":"-0.51","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.42"},{"groupId":"OG001","value":"-0.13","spread":"1.02"},{"groupId":"OG002","value":"-0.06","spread":"1.12"}]}]},{"title":"Dyspnoea, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.31"},{"groupId":"OG001","value":"-0.32","spread":"0.99"},{"groupId":"OG002","value":"-0.17","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.31"},{"groupId":"OG001","value":"-0.52","spread":"0.81"},{"groupId":"OG002","value":"-0.17","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.66"},{"groupId":"OG001","value":"-0.28","spread":"1.02"},{"groupId":"OG002","value":"-0.10","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.28"},{"groupId":"OG001","value":"-0.23","spread":"0.93"},{"groupId":"OG002","value":"-0.14","spread":"0.90"}]}]},{"title":"Dyspnoea, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.70"},{"groupId":"OG001","value":"-0.38","spread":"0.85"},{"groupId":"OG002","value":"-0.25","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.23"},{"groupId":"OG001","value":"-0.07","spread":"1.21"},{"groupId":"OG002","value":"-0.20","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.42"},{"groupId":"OG001","value":"-0.02","spread":"1.21"},{"groupId":"OG002","value":"-0.18","spread":"1.09"}]}]},{"title":"Dyspnoea, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.42"},{"groupId":"OG001","value":"-0.22","spread":"1.18"},{"groupId":"OG002","value":"0.04","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.50"},{"groupId":"OG001","value":"-0.18","spread":"1.19"},{"groupId":"OG002","value":"-0.29","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.46"},{"groupId":"OG001","value":"-0.26","spread":"1.25"},{"groupId":"OG002","value":"-0.29","spread":"1.09"}]}]},{"title":"Dyspnoea, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.42"},{"groupId":"OG001","value":"-0.24","spread":"1.24"},{"groupId":"OG002","value":"-0.20","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.35"},{"groupId":"OG001","value":"-0.26","spread":"1.23"},{"groupId":"OG002","value":"-0.03","spread":"1.09"}]}]},{"title":"Dyspnoea, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.35"},{"groupId":"OG001","value":"-0.67","spread":"0.89"},{"groupId":"OG002","value":"0.00","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.42"},{"groupId":"OG001","value":"-0.60","spread":"0.73"},{"groupId":"OG002","value":"-0.03","spread":"1.24"}]}]},{"title":"Dyspnoea, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.63","spread":"0.82"},{"groupId":"OG002","value":"-0.35","spread":"1.42"}]}]},{"title":"Dyspnoea, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.57"},{"groupId":"OG001","value":"-0.20","spread":"0.33"},{"groupId":"OG002","value":"0.23","spread":"0.92"}]}]},{"title":"Dyspnoea, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"-0.24","spread":"0.31"},{"groupId":"OG002","value":"-0.04","spread":"0.57"}]}]},{"title":"Dyspnoea, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.28"},{"groupId":"OG001","value":"-0.17","spread":"0.35"},{"groupId":"OG002","value":"-0.30","spread":"0.74"}]}]},{"title":"Dyspnoea, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.28"},{"groupId":"OG001","value":"-0.36","spread":"0.43"},{"groupId":"OG002","value":"-0.40","spread":"0.88"}]}]},{"title":"Dyspnoea, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.00"},{"groupId":"OG001","value":"-0.40","spread":"0.47"},{"groupId":"OG002","value":"0.10","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.28"},{"groupId":"OG001","value":"-0.27","spread":"0.50"},{"groupId":"OG002","value":"-0.40","spread":"0.94"}]}]},{"title":"Dyspnoea, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"-0.15","spread":"0.34"},{"groupId":"OG002","value":"-0.45","spread":"0.91"}]}]},{"title":"Dyspnoea, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.42"},{"groupId":"OG001","value":"-0.20","spread":"0.40"},{"groupId":"OG002","value":"-1.30","spread":"0.14"}]}]},{"title":"Dyspnoea, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00"},{"groupId":"OG001","value":"-0.35","spread":"0.44"},{"groupId":"OG002","value":"-0.47","spread":"1.14"}]}]},{"title":"Dyspnoea, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.27","spread":"0.50"},{"groupId":"OG002","value":"-1.30","spread":"0.14"}]}]},{"title":"Dyspnoea, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"-0.40","spread":"0.28"},{"groupId":"OG002","value":"-0.67","spread":"1.10"}]}]},{"title":"Dyspnoea, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.57"},{"groupId":"OG001","value":"-0.20","spread":"0.53"},{"groupId":"OG002","value":"-0.73","spread":"1.17"}]}]},{"title":"Dyspnoea, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.28"},{"groupId":"OG001","value":"-0.60","spread":"0.28"},{"groupId":"OG002","value":"-1.20","spread":"0.28"}]}]},{"title":"Dyspnoea, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00"},{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.20","spread":"0.57"}]}]},{"title":"Dyspnoea, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.40","spread":"0.28"}]}]},{"title":"Dyspnoea, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.10","spread":"0.42"}]}]},{"title":"Dyspnoea, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.30","spread":"0.14"}]}]},{"title":"Dyspnoea, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.30","spread":"0.14"}]}]},{"title":"Dyspnoea, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Dyspnoea, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.80"},{"groupId":"OG002","value":"-1.20"}]}]},{"title":"Dyspnoea, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.00"}]}]},{"title":"Dyspnoea, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.20"}]}]},{"title":"Dyspnoea, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"-1.20"}]}]},{"title":"Dyspnoea, Time of First Pd","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"1.06"},{"groupId":"OG001","value":"0.42","spread":"0.95"},{"groupId":"OG002","value":"0.27","spread":"1.13"}]}]},{"title":"Dyspnoea, Time of Last Tx Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.91"},{"groupId":"OG001","value":"0.28","spread":"1.01"},{"groupId":"OG002","value":"0.28","spread":"1.00"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"1.09"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.89"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.06"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.91"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"1.02"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"1.09"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"1.36"}]}]},{"title":"Dyspnoea, Survival Follow-Up Month 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)","description":"PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"343"},{"groupId":"OG001","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"5.7","upperLimit":"7.1"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.5","upperLimit":"6.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.4007","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.930","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.784","ciUpperLimit":"1.102"}]},{"type":"SECONDARY","title":"OS in the ITT Population (Arm A and Arm B)","description":"OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 39 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"343"},{"groupId":"OG001","value":"338"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","lowerLimit":"12.3","upperLimit":"16.8"},{"groupId":"OG001","value":"12.6","lowerLimit":"11.6","upperLimit":"14.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"Percentage of participants with at least one adverse event.","populationDescription":"The safety population included all treated patients, defined as randomized patients who received any protocol treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to approximately 68 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"334"},{"groupId":"OG002","value":"332"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0"},{"groupId":"OG001","value":"99.4"},{"groupId":"OG002","value":"97.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab","description":"Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.","populationDescription":"The baseline ADA evaluable population for each study treatment included participants who had a baseline ADA result. The post-baseline ADA evaluable population for each study treatment included participants who had at least one post baseline ADA result and who had received at least one dose of that study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to approximately 30 months after first participant enrolled","groups":[{"id":"OG000","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"343"}]}],"classes":[{"title":"Baseline evaluable participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"320"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"1.9"}]}]},{"title":"Post-baseline evaluable participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.1"},{"groupId":"OG001","value":"21.4"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Atezolizumab Concentration (Cmax)","description":"Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.","populationDescription":"The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"µg/mL","timeFrame":"Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"328"}]}],"classes":[{"title":"Cycle 1 Day 1 Post dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"302"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":"116"},{"groupId":"OG001","value":"378","spread":"124"}]}]},{"title":"Cycle 3 Day 1 Post dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"470","spread":"147"},{"groupId":"OG001","value":"444","spread":"119"}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Atezolizumab Concentration (Cmin)","description":"Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.","populationDescription":"The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"µg/mL","timeFrame":"Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)","groups":[{"id":"OG000","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"328"}]}],"classes":[{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"308"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the level of detection."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Below the level of detection."}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"285"},{"groupId":"OG001","value":"289"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":"29.9"},{"groupId":"OG001","value":"69.5","spread":"34.7"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"281"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":"40.1"},{"groupId":"OG001","value":"107","spread":"52.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"252"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":"62.3"},{"groupId":"OG001","value":"126","spread":"68.4"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":"80.4"},{"groupId":"OG001","value":"190","spread":"84.6"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":"79.2"},{"groupId":"OG001","value":"212","spread":"78.1"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":"90.4"},{"groupId":"OG001","value":"224","spread":"134"}]}]},{"title":"Cycle 32 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":"88.4"},{"groupId":"OG001","value":"210","spread":"102"}]}]},{"title":"Cycle 40 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"308","spread":"141"},{"groupId":"OG001","value":"174","spread":"NA","comment":"Not evaluable; only 1 participant."}]}]},{"title":"Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":"93.7"},{"groupId":"OG001","value":"137","spread":"103"}]}]},{"title":"Day 120 Post Last Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.81","spread":"9.76"},{"groupId":"OG001","value":"9.47","spread":"13.1"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations for Paclitaxel","description":"Plasma concentrations for paclitaxel.","populationDescription":"The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)","groups":[{"id":"OG000","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"classes":[{"title":"Cycle 1 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the level of detection."}]}]},{"title":"Cycle 1 Day 1 Before end of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5860","spread":"2410"}]}]},{"title":"Cycle 1 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2960","spread":"2770"}]}]},{"title":"Cycle 3 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the threshold of the assay."}]}]},{"title":"Cycle 3 Day 1 Before end of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21900","spread":"42600"}]}]},{"title":"Cycle 3 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11000","spread":"30700"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations for Nab-Paclitaxel","description":"Plasma concentrations for nab-paclitaxel.","populationDescription":"The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)","groups":[{"id":"OG000","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"38"}]}],"classes":[{"title":"Cycle 1 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the level of detection."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Below the level of detection."}]}]},{"title":"Cycle 1 Day 1 Before End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3330","spread":"3680"},{"groupId":"OG001","value":"8160","spread":"20900"}]}]},{"title":"Cycle 1 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"735","spread":"1300"},{"groupId":"OG001","value":"921","spread":"2080"}]}]},{"title":"Cycle 3 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the threshold of the assay."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Below the threshold of the assay."}]}]},{"title":"Cycle 3 Day 1 Before End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7160","spread":"12300"},{"groupId":"OG001","value":"7180","spread":"14400"}]}]},{"title":"Cycle 3 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"296","spread":"274"},{"groupId":"OG001","value":"1140","spread":"2070"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations for Carboplatin","description":"Plasma concentrations for carboplatin.","populationDescription":"The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)","groups":[{"id":"OG000","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant."},{"id":"OG002","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"39"}]}],"classes":[{"title":"Cycle 1 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Below the level of detection."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Below the level of detection."},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Below the level of detection."}]}]},{"title":"Cycle 1 Day 1 Before End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21100","spread":"12400"},{"groupId":"OG001","value":"15900","spread":"9270"},{"groupId":"OG002","value":"24900","spread":"38200"}]}]},{"title":"Cycle 1 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11900","spread":"6410"},{"groupId":"OG001","value":"9890","spread":"4780"},{"groupId":"OG002","value":"10800","spread":"6230"}]}]},{"title":"Cycle 3 Day 1 Prior to Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"238","spread":"276"},{"groupId":"OG001","value":"147","spread":"60.9"},{"groupId":"OG002","value":"161","spread":"70.0"}]}]},{"title":"Cycle 3 Day 1 Before End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33800","spread":"38600"},{"groupId":"OG001","value":"23500","spread":"21600"},{"groupId":"OG002","value":"26800","spread":"31900"}]}]},{"title":"Cycle 3 Day 1 After Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20000","spread":"30900"},{"groupId":"OG001","value":"11200","spread":"5160"},{"groupId":"OG002","value":"14700","spread":"14600"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the first study drug administration to the data cutoff date: 17 February 2021 (up to approximately 68 months).","description":"All-cause mortality is reported for deaths that occurred during the study based on the ITT population, which included all randomized participants. Serious and other adverse events were reported based on the safety population, which included all randomized participants who received at least one dose of any study medication.","eventGroups":[{"id":"EG000","title":"Arm C: Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care.","deathsNumAffected":252,"deathsNumAtRisk":340,"seriousNumAffected":96,"seriousNumAtRisk":334,"otherNumAffected":315,"otherNumAtRisk":334},{"id":"EG001","title":"Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.","deathsNumAffected":245,"deathsNumAtRisk":343,"seriousNumAffected":168,"seriousNumAtRisk":334,"otherNumAffected":325,"otherNumAtRisk":334},{"id":"EG002","title":"Arm A: Atezolizumab + Paclitaxel + Carboplatin","description":"The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant.","deathsNumAffected":243,"deathsNumAtRisk":338,"seriousNumAffected":151,"seriousNumAtRisk":332,"otherNumAffected":315,"otherNumAtRisk":332}],"seriousEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":334},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":332}]},{"term":"FEBRILE NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":334},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":334},{"groupId":"EG002","numEvents":16,"numAffected":16,"numAtRisk":332}]},{"term":"HAEMOLYSIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"PANCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ACUTE MYOCARDIAL INFARCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"ANGINA UNSTABLE","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":332}]},{"term":"ATRIAL FLUTTER","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":332}]},{"term":"ATRIAL THROMBOSIS","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BRADYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CARDIAC ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"CARDIAC FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"CARDIAC FAILURE ACUTE","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"CARDIAC TAMPONADE","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CARDIO-RESPIRATORY ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CORONARY ARTERY STENOSIS","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"LEFT VENTRICULAR DYSFUNCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"MYOCARDIAL INFARCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PERICARDIAL EFFUSION","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"SINUS TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"TRACHEO-OESOPHAGEAL FISTULA","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ADRENAL INSUFFICIENCY","organSystem":"Endocrine disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPERTHYROIDISM","organSystem":"Endocrine disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOPITUITARISM","organSystem":"Endocrine disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"RETINAL DETACHMENT","organSystem":"Eye disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ANAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"COLITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":334},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":334},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":332}]},{"term":"DUODENAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"DYSPHAGIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"ENTEROCOLITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"GASTRIC ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GASTROINTESTINAL NECROSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GASTROINTESTINAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GASTROINTESTINAL TOXICITY","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"INGUINAL HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INTESTINAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"LARGE INTESTINE PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"OESOPHAGITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PANCREATITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PANCREATITIS CHRONIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"RECTAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"SMALL INTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"UPPER GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":332}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":332}]},{"term":"DEATH","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"GAIT DISTURBANCE","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"MALAISE","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"MUCOSAL INFLAMMATION","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"NON-CARDIAC CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"OEDEMA","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PAIN","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PERFORMANCE STATUS DECREASED","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":334},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":334},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":332}]},{"term":"AUTOIMMUNE HEPATITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BILE DUCT STONE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CHOLECYSTITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":332}]},{"term":"CHOLECYSTITIS ACUTE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DRUG-INDUCED LIVER INJURY","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HEPATIC FUNCTION ABNORMAL","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HEPATITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HEPATITIS TOXIC","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"IMMUNE-MEDIATED HEPATITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ANAPHYLACTIC REACTION","organSystem":"Immune system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"DRUG HYPERSENSITIVITY","organSystem":"Immune system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS","organSystem":"Immune system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ABDOMINAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ABDOMINAL SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"APPENDICITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BACTERAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BRONCHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":332}]},{"term":"CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CHRONIC HEPATITIS C","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CLOSTRIDIUM DIFFICILE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"COLONIC ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ENDOCARDITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ENTEROCOLITIS INFECTIOUS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"GASTROENTERITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HEPATITIS B","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"INFECTED DERMAL CYST","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INFLUENZA","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"LOWER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"LUNG ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"MENINGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"OSTEOMYELITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PLEURAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":334},{"groupId":"EG001","numEvents":37,"numAffected":33,"numAtRisk":334},{"groupId":"EG002","numEvents":32,"numAffected":30,"numAtRisk":332}]},{"term":"PNEUMONIA BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PNEUMONIA HAEMOPHILUS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PNEUMONIA STAPHYLOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PNEUMONIA STREPTOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PSEUDOMONAL SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PULMONARY SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":332}]},{"term":"RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":332}]},{"term":"SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":334},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":334},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":332}]},{"term":"SEPTIC SHOCK","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SINUSITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"STOMATOCOCCAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"URINARY TRACT INFECTION STAPHYLOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"UROSEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"VASCULAR DEVICE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ALCOHOL POISONING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CHEST INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"FALL","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"FEMORAL NECK FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"FEMUR FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HIP FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"HUMERUS FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INFUSION RELATED REACTION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"PERIORBITAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"RADIATION OESOPHAGITIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"RADIATION PNEUMONITIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"RIB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SKIN LACERATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SUBDURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"THORACIC VERTEBRAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"TOXICITY TO VARIOUS AGENTS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BLOOD BILIRUBIN INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BLOOD CREATININE INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BLOOD LACTIC ACID INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GENERAL PHYSICAL CONDITION ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":332}]},{"term":"LIVER FUNCTION TEST ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"NEUTROPHIL COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":332}]},{"term":"PLATELET COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"WEIGHT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":332}]},{"term":"DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"FAILURE TO THRIVE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPERCALCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"HYPERGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPERKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOCALCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOMAGNESAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPONATRAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"TYPE 2 DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":332}]},{"term":"FLANK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"MUSCULOSKELETAL CHEST PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"OSTEONECROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"OSTEONECROSIS OF JAW","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PATHOLOGICAL FRACTURE","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"POLYARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"POLYMYOSITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ADENOCARCINOMA OF COLON","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BENIGN SALIVARY GLAND NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"BLADDER CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"COLON CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GALLBLADDER ADENOCARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INFECTED NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"MYELODYSPLASTIC SYNDROME","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PROSTATE CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"TUMOUR EMBOLISM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BRAIN OEDEMA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"CEREBRAL ISCHAEMIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CEREBROVASCULAR ACCIDENT","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":332}]},{"term":"DEPRESSED LEVEL OF CONSCIOUSNESS","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"EMBOLIC STROKE","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"EPILEPSY","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"GUILLAIN-BARRE SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HEMIPLEGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HYPERAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOTONIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ISCHAEMIC STROKE","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"MOTOR DYSFUNCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"MYXOEDEMA COMA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PARAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SEIZURE","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SPINAL CORD COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"SYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"TRANSIENT ISCHAEMIC ATTACK","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"DEVICE DISLOCATION","organSystem":"Product Issues","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"COMPLETED SUICIDE","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"CONFUSIONAL STATE","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HALLUCINATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"MENTAL STATUS CHANGES","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"SUICIDAL IDEATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ACUTE KIDNEY INJURY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"HYDRONEPHROSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"URINARY RETENTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PROSTATITIS","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ACUTE RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ASPIRATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ATELECTASIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"BRONCHIAL HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":334},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":332}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"DIAPHRAGMATIC PARALYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":334},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":332}]},{"term":"DYSPNOEA AT REST","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DYSPNOEA EXERTIONAL","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"EMPHYSEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"EPISTAXIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":334},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":332}]},{"term":"HYPOXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"IMMUNE-MEDIATED PNEUMONITIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"INTERSTITIAL LUNG DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"LARYNGEAL HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"LUNG CONSOLIDATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"LUNG DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PARANASAL CYST","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":332}]},{"term":"PNEUMONIA ASPIRATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"PNEUMONITIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":334},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":332}]},{"term":"PNEUMOTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"PNEUMOTHORAX SPONTANEOUS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":332}]},{"term":"PULMONARY OEDEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":332}]},{"term":"DERMATITIS ACNEIFORM","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ERYTHEMA MULTIFORME","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":332}]},{"term":"THERAPEUTIC EMBOLISATION","organSystem":"Surgical and medical procedures","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"TRANSURETHRAL PROSTATECTOMY","organSystem":"Surgical and medical procedures","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"ARTERIAL STENOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ARTERITIS","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"DEEP VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"EMBOLISM","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HAEMODYNAMIC INSTABILITY","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"ORTHOSTATIC HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PERIPHERAL ARTERIAL OCCLUSIVE DISEASE","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"PERIPHERAL ISCHAEMIA","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":332}]},{"term":"SUPERIOR VENA CAVA SYNDROME","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]},{"term":"THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":334},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":334},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":332}]}],"otherEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":244,"numAffected":193,"numAtRisk":334},{"groupId":"EG001","numEvents":257,"numAffected":188,"numAtRisk":334},{"groupId":"EG002","numEvents":153,"numAffected":131,"numAtRisk":332}]},{"term":"LEUKOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":34,"numAtRisk":334},{"groupId":"EG001","numEvents":86,"numAffected":42,"numAtRisk":334},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":332}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":214,"numAffected":124,"numAtRisk":334},{"groupId":"EG001","numEvents":261,"numAffected":121,"numAtRisk":334},{"groupId":"EG002","numEvents":61,"numAffected":43,"numAtRisk":332}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":171,"numAffected":92,"numAtRisk":334},{"groupId":"EG001","numEvents":163,"numAffected":91,"numAtRisk":334},{"groupId":"EG002","numEvents":66,"numAffected":46,"numAtRisk":332}]},{"term":"HYPOTHYROIDISM","organSystem":"Endocrine disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":334},{"groupId":"EG001","numEvents":40,"numAffected":34,"numAtRisk":334},{"groupId":"EG002","numEvents":30,"numAffected":27,"numAtRisk":332}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":334},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":334},{"groupId":"EG002","numEvents":20,"numAffected":18,"numAtRisk":332}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":334},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":334},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":332}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":73,"numAtRisk":334},{"groupId":"EG001","numEvents":126,"numAffected":101,"numAtRisk":334},{"groupId":"EG002","numEvents":94,"numAffected":75,"numAtRisk":332}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":107,"numAffected":77,"numAtRisk":334},{"groupId":"EG001","numEvents":135,"numAffected":92,"numAtRisk":334},{"groupId":"EG002","numEvents":116,"numAffected":94,"numAtRisk":332}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":137,"numAffected":97,"numAtRisk":334},{"groupId":"EG001","numEvents":206,"numAffected":131,"numAtRisk":334},{"groupId":"EG002","numEvents":139,"numAffected":94,"numAtRisk":332}]},{"term":"STOMATITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":334},{"groupId":"EG001","numEvents":27,"numAffected":22,"numAtRisk":334},{"groupId":"EG002","numEvents":24,"numAffected":20,"numAtRisk":332}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":48,"numAtRisk":334},{"groupId":"EG001","numEvents":88,"numAffected":67,"numAtRisk":334},{"groupId":"EG002","numEvents":64,"numAffected":50,"numAtRisk":332}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":66,"numAtRisk":334},{"groupId":"EG001","numEvents":81,"numAffected":58,"numAtRisk":334},{"groupId":"EG002","numEvents":101,"numAffected":77,"numAtRisk":332}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":334},{"groupId":"EG001","numEvents":31,"numAffected":25,"numAtRisk":334},{"groupId":"EG002","numEvents":35,"numAffected":28,"numAtRisk":332}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":88,"numAtRisk":334},{"groupId":"EG001","numEvents":137,"numAffected":107,"numAtRisk":334},{"groupId":"EG002","numEvents":112,"numAffected":97,"numAtRisk":332}]},{"term":"MALAISE","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":16,"numAtRisk":334},{"groupId":"EG001","numEvents":26,"numAffected":18,"numAtRisk":334},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":332}]},{"term":"MUCOSAL INFLAMMATION","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":334},{"groupId":"EG001","numEvents":23,"numAffected":16,"numAtRisk":334},{"groupId":"EG002","numEvents":17,"numAffected":17,"numAtRisk":332}]},{"term":"OEDEMA PERIPHERAL","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":22,"numAtRisk":334},{"groupId":"EG001","numEvents":32,"numAffected":25,"numAtRisk":334},{"groupId":"EG002","numEvents":28,"numAffected":23,"numAtRisk":332}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":34,"numAtRisk":334},{"groupId":"EG001","numEvents":66,"numAffected":45,"numAtRisk":334},{"groupId":"EG002","numEvents":68,"numAffected":46,"numAtRisk":332}]},{"term":"NASOPHARYNGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":334},{"groupId":"EG001","numEvents":28,"numAffected":21,"numAtRisk":334},{"groupId":"EG002","numEvents":35,"numAffected":23,"numAtRisk":332}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":334},{"groupId":"EG001","numEvents":30,"numAffected":29,"numAtRisk":334},{"groupId":"EG002","numEvents":28,"numAffected":23,"numAtRisk":332}]},{"term":"RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":334},{"groupId":"EG001","numEvents":17,"numAffected":10,"numAtRisk":334},{"groupId":"EG002","numEvents":38,"numAffected":25,"numAtRisk":332}]},{"term":"UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":334},{"groupId":"EG001","numEvents":24,"numAffected":18,"numAtRisk":334},{"groupId":"EG002","numEvents":30,"numAffected":18,"numAtRisk":332}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":16,"numAtRisk":334},{"groupId":"EG001","numEvents":45,"numAffected":26,"numAtRisk":334},{"groupId":"EG002","numEvents":27,"numAffected":18,"numAtRisk":332}]},{"term":"ALANINE AMINOTRANSFERASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":18,"numAtRisk":334},{"groupId":"EG001","numEvents":64,"numAffected":40,"numAtRisk":334},{"groupId":"EG002","numEvents":56,"numAffected":34,"numAtRisk":332}]},{"term":"ASPARTATE AMINOTRANSFERASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":17,"numAtRisk":334},{"groupId":"EG001","numEvents":64,"numAffected":34,"numAtRisk":334},{"groupId":"EG002","numEvents":56,"numAffected":31,"numAtRisk":332}]},{"term":"BLOOD ALKALINE PHOSPHATASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":334},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":334},{"groupId":"EG002","numEvents":33,"numAffected":25,"numAtRisk":332}]},{"term":"BLOOD CREATININE INCREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":28,"numAffected":25,"numAtRisk":334},{"groupId":"EG002","numEvents":16,"numAffected":16,"numAtRisk":332}]},{"term":"NEUTROPHIL COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":144,"numAffected":65,"numAtRisk":334},{"groupId":"EG001","numEvents":132,"numAffected":60,"numAtRisk":334},{"groupId":"EG002","numEvents":25,"numAffected":18,"numAtRisk":332}]},{"term":"PLATELET COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":110,"numAffected":59,"numAtRisk":334},{"groupId":"EG001","numEvents":128,"numAffected":59,"numAtRisk":334},{"groupId":"EG002","numEvents":64,"numAffected":40,"numAtRisk":332}]},{"term":"WEIGHT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":334},{"groupId":"EG001","numEvents":38,"numAffected":32,"numAtRisk":334},{"groupId":"EG002","numEvents":22,"numAffected":21,"numAtRisk":332}]},{"term":"WHITE BLOOD CELL COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":36,"numAtRisk":334},{"groupId":"EG001","numEvents":64,"numAffected":32,"numAtRisk":334},{"groupId":"EG002","numEvents":19,"numAffected":12,"numAtRisk":332}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":98,"numAffected":84,"numAtRisk":334},{"groupId":"EG001","numEvents":110,"numAffected":82,"numAtRisk":334},{"groupId":"EG002","numEvents":109,"numAffected":93,"numAtRisk":332}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":334},{"groupId":"EG001","numEvents":33,"numAffected":23,"numAtRisk":334},{"groupId":"EG002","numEvents":30,"numAffected":20,"numAtRisk":332}]},{"term":"HYPERGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":334},{"groupId":"EG001","numEvents":29,"numAffected":18,"numAtRisk":334},{"groupId":"EG002","numEvents":28,"numAffected":25,"numAtRisk":332}]},{"term":"HYPOKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":23,"numAtRisk":334},{"groupId":"EG001","numEvents":39,"numAffected":30,"numAtRisk":334},{"groupId":"EG002","numEvents":30,"numAffected":24,"numAtRisk":332}]},{"term":"HYPOMAGNESAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":38,"numAtRisk":334},{"groupId":"EG001","numEvents":91,"numAffected":54,"numAtRisk":334},{"groupId":"EG002","numEvents":47,"numAffected":35,"numAtRisk":332}]},{"term":"HYPONATRAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":334},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":334},{"groupId":"EG002","numEvents":22,"numAffected":17,"numAtRisk":332}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":33,"numAtRisk":334},{"groupId":"EG001","numEvents":78,"numAffected":53,"numAtRisk":334},{"groupId":"EG002","numEvents":107,"numAffected":78,"numAtRisk":332}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":334},{"groupId":"EG001","numEvents":40,"numAffected":35,"numAtRisk":334},{"groupId":"EG002","numEvents":38,"numAffected":33,"numAtRisk":332}]},{"term":"BONE PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":334},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":334},{"groupId":"EG002","numEvents":36,"numAffected":23,"numAtRisk":332}]},{"term":"MYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":19,"numAtRisk":334},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":334},{"groupId":"EG002","numEvents":63,"numAffected":44,"numAtRisk":332}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":334},{"groupId":"EG001","numEvents":35,"numAffected":32,"numAtRisk":334},{"groupId":"EG002","numEvents":48,"numAffected":35,"numAtRisk":332}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":33,"numAtRisk":334},{"groupId":"EG001","numEvents":38,"numAffected":32,"numAtRisk":334},{"groupId":"EG002","numEvents":35,"numAffected":33,"numAtRisk":332}]},{"term":"DYSGEUSIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":334},{"groupId":"EG001","numEvents":30,"numAffected":26,"numAtRisk":334},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":332}]},{"term":"HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":18,"numAtRisk":334},{"groupId":"EG001","numEvents":40,"numAffected":33,"numAtRisk":334},{"groupId":"EG002","numEvents":44,"numAffected":38,"numAtRisk":332}]},{"term":"NEUROPATHY PERIPHERAL","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":36,"numAtRisk":334},{"groupId":"EG001","numEvents":39,"numAffected":34,"numAtRisk":334},{"groupId":"EG002","numEvents":73,"numAffected":66,"numAtRisk":332}]},{"term":"PARAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":334},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":334},{"groupId":"EG002","numEvents":33,"numAffected":28,"numAtRisk":332}]},{"term":"PERIPHERAL SENSORY NEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":30,"numAtRisk":334},{"groupId":"EG001","numEvents":54,"numAffected":48,"numAtRisk":334},{"groupId":"EG002","numEvents":68,"numAffected":55,"numAtRisk":332}]},{"term":"ANXIETY","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":334},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":334},{"groupId":"EG002","numEvents":17,"numAffected":17,"numAtRisk":332}]},{"term":"INSOMNIA","organSystem":"Psychiatric disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":334},{"groupId":"EG001","numEvents":34,"numAffected":30,"numAtRisk":334},{"groupId":"EG002","numEvents":32,"numAffected":29,"numAtRisk":332}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":51,"numAtRisk":334},{"groupId":"EG001","numEvents":85,"numAffected":65,"numAtRisk":334},{"groupId":"EG002","numEvents":69,"numAffected":62,"numAtRisk":332}]},{"term":"DYSPHONIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":334},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":334},{"groupId":"EG002","numEvents":17,"numAffected":17,"numAtRisk":332}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":57,"numAtRisk":334},{"groupId":"EG001","numEvents":100,"numAffected":68,"numAtRisk":334},{"groupId":"EG002","numEvents":75,"numAffected":64,"numAtRisk":332}]},{"term":"EPISTAXIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":37,"numAtRisk":334},{"groupId":"EG001","numEvents":44,"numAffected":34,"numAtRisk":334},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":332}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":18,"numAtRisk":334},{"groupId":"EG001","numEvents":29,"numAffected":19,"numAtRisk":334},{"groupId":"EG002","numEvents":20,"numAffected":18,"numAtRisk":332}]},{"term":"ALOPECIA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":103,"numAffected":102,"numAtRisk":334},{"groupId":"EG001","numEvents":114,"numAffected":114,"numAtRisk":334},{"groupId":"EG002","numEvents":134,"numAffected":130,"numAtRisk":332}]},{"term":"DRY SKIN","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":334},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":334},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":332}]},{"term":"PRURITUS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":334},{"groupId":"EG001","numEvents":36,"numAffected":24,"numAtRisk":334},{"groupId":"EG002","numEvents":42,"numAffected":32,"numAtRisk":332}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":334},{"groupId":"EG001","numEvents":55,"numAffected":47,"numAtRisk":334},{"groupId":"EG002","numEvents":57,"numAffected":44,"numAtRisk":332}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MeDRA Version 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":334},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":334},{"groupId":"EG002","numEvents":25,"numAffected":22,"numAtRisk":332}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-10-24","uploadDate":"2019-09-25T13:06","filename":"Prot_000.pdf","size":3651648},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-01-11","uploadDate":"2019-09-25T13:06","filename":"SAP_001.pdf","size":921776}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Switzerland"]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"},{"id":"D000906","term":"Antibodies"},{"id":"D016190","term":"Carboplatin"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D017239","term":"Paclitaxel"}],"ancestors":[{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}